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ABSTRACT

A review of gene delivery methods and gene editing methods, as well as original
research utilizing DNA as a delivery vehicle is presented in the following thesis.
Thousands of diseases have been linked to genes. Gene therapy, either delivering
therapeutic genes or editing DNA bases, has arisen as a treatment option with the
potential to cure diseases, rather than just ease symptoms. Genes and editing tools need to
be delivered to cells for these therapies to be effective and many techniques have been
developed to address the issue of delivery. Nonviral and viral methods have been used to
deliver nucleic acids and several different protein systems have been employed to edit
genes. Gene therapy will continue to evolve as delivery are improved. Along with being
delivered as a therapeutic molecule, DNA has been investigated as a carrier itself. DNA
origami, have been utilized to deliver chemotherapies to breast cancer. Globally, millions
of women are affected by breast cancer each year. DNA origami was analyzed as a
carrier for the chemotherapy Doxorubicin (DOX) in two triple negative breast cancer
(TNBC) cell lines, a type of breast cancer with few treatments. The killing efficiency and
uptake of DOX loaded into a model DNA origami triangle (DOX-DNA-T) were
elucidated. Inhibition of various pathways revealed DOX-DNA-T was internalization by
multiple energy-dependent pathways. DOX-DNA-T altered the subcellular localization of
DOX and increased the concentration of DOX inside cells. A delayed killing was
observed with DOX-DNA-T compared to free DOX, but the carrier was able to modulate
the toxicity between cell lines. Overall, DNA delivery is able to treat various disease
conditions and DNA origami is an interesting carrier for therapeutics.
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SECTION

1. INTRODUCTION

Here, a review of DNA delivery and genome editing techniques are presented, as
well as original research over the uptake and cytotoxicity of DNA nanostructures, also
known as DNA origami. The original research has the potential to improve the
therapeutic efficacy of DNA origami as a carrier system.
Predisposition to and development of certain diseases have been linked with
specific genes [1]. Many genetic diseases are due to simple mutations in one gene, such
as sickle cell anemia, cystic fibrosis, and Huntington’s disease [2-4]. Historically, genetic
diseases have not been able to be cured, with symptoms only being able to be modulated
with drugs. Traditional protein and small molecule drugs used to treat genetic diseases
often have pharmacokinetic issues [1]. However, with current technology, these diseases
can be cured by supplying diseased cells with functional genes or correcting a mutated
gene.
DNA, the material encoding all of instructions required for life, has been utilized
as a therapeutic molecule and more recently to deliver other therapies to cells. Delivery
of compounds across target cell membranes is essential for function inside cells. Nucleic
acid and therapeutic molecule delivery have been achieved using a variety of different
methods. However, delivery methods are constantly improving and the optimal carriers
for different systems are still sought.
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Many methods have been developed in an attempt to deliver therapeutic nucleic
acids or genome editing tools for genome correcting, each with varying effectivity,
cytotoxicity, immunogenicity, and sustainable effects [1, 5]. Delivery strategies fall into
two main categories: viral and nonviral. Nonviral methods rely on physical
(microinjection, bioballistics, hydrodynamic force, ultrasonic nebulization, and
electroporation) or chemical (calcium phosphate co-precipitation, lipofection, and cellpenetrating peptides) cell membrane infiltration [5-13]. A variety of viruses have also
been used for delivery and to overcome the cell membrane, including adenoviruses,
adeno-associated viruses, and retroviruses [14]. Zinc finger nucleases (ZFNs),
transcription activator-like effector nucleases (TALENs), and CRISPR-Cas systems have
been utilized to target and correct defective genes after delivery into cells [1]. These
subjects are further reviewed in Paper I.
Our understanding of DNA has allowed us to develop methods to reprogram cells,
including technologies that can edit genes. Our ability to program DNA also gave rise to
a method to fold the nucleic acid into new and accurate shapes in 2006 [15, 16]. Most
nanostructures and nanoparticles used for delivery are not programmable; it can be
difficult to control their size uniformly and their shapes are often limited to spheres [17].
The geometry of nanostructures can affect their biodistribution, their movement through
fluids, and their cellular internalization [17]. The use of DNA allows for high precision
design of geometry and easy functionalization [15, 18]. The design and flexibility of
DNA nanostructures, or DNA origami, is optimal for a drug carrier system. However,
degradation in vivo by endogenous endonucleases is a large concern [16].

3
DNA origami has been utilized for chemotherapy delivery and cancer treatment.
Millions of women are diagnosed each year with breast cancer [19]. Triple negative
breast cancers (TNBCs), a particularly devastating form of breast cancer [20, 21], lack
treatment options because they do not respond to frequently used cancer therapies [22].
Often, harsh nonspecific chemotherapies are used in combination with surgery [21, 23,
24]. One such chemotherapy is Doxorubicin (DOX) [25]. DNA origami has been used to
delivery DOX to cancer cells, as DOX intercalates into the DNA double helix [25, 26].
These nanostructures have been shown to have high passive accumulation within tumors
and increase drug delivery to the tumor site [18, 27]. Using nanocarriers to directly
deliver drugs to tumors can increase retention time to combat drug resistance and can
reduce overall toxicity in patients [15, 28, 29].
Although DNA origami have been used for the delivery of chemotherapeutic
drugs, their exact uptake mechanism is not entirely understood, an important aspect
which influences drug delivery efficacy. Paper II discusses original research utilizing
DNA origami to deliver DOX to breast cancer cells. The killing efficiency, uptake
mechanism, and subcellular localization of a model DNA origami triangle were
determined in two TNBC cell lines. It was found that DNA nanostructures facilitate drug
entry, have delayed toxicity and release of drugs, and are internalized by energydependent pathways. Localization was time- and concentration-dependent.
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PAPER

I. EVOLUTIONARY TIMELINE OF GENETIC DELIVERY AND GENE
THERAPY

Natalie J. Holla, Han-Jung Leeb, and Yue-Wern Huanga*
aDepartment of Biological Sciences, College of Arts, Sciences, and Business, Missouri
University of Science and Technology, Rolla, MO 65409, USA;
bDepartment of Natural Resources and Environmental Studies, College of Environmental
Studies, National Dong Hwa University, Hualien 97401, Taiwan

ABSTRACT

There are more than 3,500 genes that are being linked to hereditary diseases or
correlated with elevated risk of certain illnesses. As an alternative to conventional
treatments with small molecule drugs, gene therapy has arisen as an effective treatment
with the potential to not just alleviate disease conditions but also to possibly cure them
completely. In order for these treatment regimens to work, genes or editing tools intended
to correct diseased genetic material must be efficiently delivered to target sites. There
have been many techniques developed to achieve such a goal. In this article, we
systematically review a variety of gene delivery and therapy methods that include
physical methods, chemical and biochemical methods, viral methods, and genome
editing. We discuss their historical discovery, mechanisms, advantages, limitations,
safety, and perspective.
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1. INTRODUCTION

Hereditary diseases and disease predisposition have been associated with
particular genes. Over 3,000 genes have been linked to hereditary illnesses and around
500 have been identified that increase risk for certain diseases [1]. For example, cystic
fibrosis is a recessive illness occurring in individuals carrying two copies of a mutant
CFTR (cystic fibrosis transmembrane conductance regulator) gene [2]. Patients carrying
two recessive P-globin genes with a single base substitution present with sickle cell
anemia [3] and patients with one copy of a dominant mutation in the huntingtin (HTT)
gene develop Huntington’s disease [4]. Historically, these diseases are not curable and
symptoms can only be managed. Some treatments, such as proteins and small molecules,
are difficult to apply due to bioavailability, stability, specific targeting, and other
pharmacokinetics issues [1].
The idea of gene therapy first arose in the 1970s [5]. Initial applications focused
on gene replacement therapy to treat inherited disorders by supplying target cells with a
copy of a normal gene. In the last fifty years, these delivered treatments have advanced to
include protein-coding cDNA sequences and non-coding small nucleic acids that regulate
a broad spectrum of cellular behaviors and functions. Both of which are becoming
mainstream therapies and hold tremendous potential in revolutionizing medicine. In
addition to replacing a target gene, protein-coding cDNAs are being widely used to
manipulate neurotrophic factors in neurodegenerative diseases such as Parkinson’s and
Alzheimer’s diseases, modulate regulatory proteins that involve cell survival and
apoptosis of cancer, produce angiogenic factors in cardiac ischemia, and immune-
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modulate HIV and other immune diseases [6]. In the past decade, non-coding small
nucleic acids represent a new shift of paradigm in gene therapy. Non-coding nucleic acids
include oligonucleotides, catalytic RNAs or DNAs, antisense RNAs, and aptamers. These
non-coding nucleic acids have been used to completely silence or partially regulate
functions of certain genes to mitigate disease severity or progression in cancer,
neurodegenerative diseases, and cardiovascular diseases, among others [7-9].
Missing genes may be added into cells using various techniques in order to
combat illnesses [10-13]. Genome-editing technologies may be able to edit or replace
defective genes and eliminate genetic diseases all together [1]. Genome editing is the key
to advancing treatment of inheritable diseases and human medicine. In theory, these
techniques sound simple. In reality, the development of genome editing is sophisticated
and has experienced numerous setbacks. One of the most notable setbacks being the
death of Jesse Gelsinger in 1999, the first death associated with gene therapy [14].
Gelsinger took part in an experimental gene therapy trial to treat a rare metabolic disorder
known as ornithine transcarbamylase (OTC) deficiency. His body overreacted to the viral
vector used and he died after multiple of his organ systems failed. His death shocked the
research community and no gene therapy clinical trials relating to OTC were proposed
until 2016 [15]. This clinical case is a manifestation that efficacy and safety are equally
important in developing gene therapies.
In vitro and in vivo DNA deliveries are key to numerous aspects of life science
research which include, but are not limited to, discovery of fundamental principles in
biology (e.g., gene structure, regulation, and function), understanding the nature of
human diseases (e.g., genetic defect and correction), and biomedical applications (e.g.,
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gene therapy, drug delivery, and DNA vaccination). One of the major obstacles in DNA
delivery is the mammalian cell membrane due to its non-polar and hydrophobic nature.
Over the course of evolution, cells have survived by making their membranes selective.
On one hand, selectivity allows for the efficient passage of nutrients, minerals, and other
essential materials into cells for growth and removal of cellular wastes [16]. On the other
hand, selectivity helps fend off harmful materials from entering into cells. Polyanions,
such as nucleic acids, are poorly internalized but can be delivered into cells using various
carriers and methods. Before the benefits of DNA therapy can be relished, inefficiency in
delivery must be addressed.
Delivery of nucleic acids into mammalian cells can be generally divided into two
main strategies: viral and nonviral delivery. Nonviral delivery tools can be based on
physical methods or various classes of chemicals, such as cationic lipids, polymers,
peptides, or carbohydrate analogs [17]. Physical nonviral methods discussed in this
review encompass microinjection, bioballistics, hydrodynamic force, ultrasonic
nebulization, and electroporation. Chemical and biochemical nonviral methods include
calcium phosphate co-precipitation and membrane infiltration mediated by artificial
lipids and peptides. Importantly, small delivery peptides, termed cell-penetrating peptides
(CPPs), have gained great interest among these nonviral tools. Viral delivery of genetic
material takes advantage of the natural life cycle of viruses, using viruses with modified
or synthetic genomes to inject therapeutic genes into cells. Depending on the virus used,
delivered genes may exist as a plasmid inside cells or be integrated into the host genome.
Viral vectors discussed here include adenovirus, adeno-associated virus, gammaretrovirus, and lentivirus.
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Each delivery method has its benefits. Viral methods are efficient, but may cause
adverse immune responses. Nonviral gene transfer is likely to be nonimmunogenic, but
often suffers from lower transfection rates and toxic carriers. Nonviral methods of
delivery also are often limited by transient transfection [5], with expression of delivered
genetic material often only lasting for a short period due to low integration rates [18].
This is due to the low chance that plasmid DNA can enter the nucleus, with the only time
period to enter being when nuclear membrane is destabilized (e.g., during replication)
[19]. Integrating viral vectors have higher rates of transient transection than nonviral
vectors; however, it should be noted that integration at random locations in the genome
can result in mutagenesis and oncogenesis [1]. Nevertheless, the importance of viral
vectors as a DNA delivery tool cannot be overlooked, as they have been a pivotal partner
in revolutionary genetics, cell biology, molecular biology, and medical discoveries.
Genome editing, also known as gene editing, is defined as a group of technologies
used to change an organism's genome according to the US National Institutes of Health
(NIH) [20]. These technologies allow genetic material to be artificially added, removed,
or altered at particular locations in the genome. Many strategies are currently available
for programmable and targeted genome editing, including zinc finger nucleases (ZFNs)
and transcription activator-like effector nucleases (TALENs). The clustered regularly
interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas)
system is a next-generation genome editing technology, which is originally based on a
system used by bacteria and archaea to combat recurrent viral infections.
The number of clinical trials involving gene therapy has steadily increased over
the years, with approximately 2,600 trials up until 2017 [21]. The majority of clinical
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trials use viral vectors, including adenovirus (20.5%), retrovirus (17.9%), adenoassociated virus (7.6%), lentivirus (7.3%), vaccinia virus (6.6%), poxvirus (4%), and
herpes simplex virus (3.5%). Naked DNA (16.6%), often in combination with
electroporation, and lipofection (4.4%) are the most common nonviral methods used in
clinical trials [21]. It should be kept in mind that certain types of delivery methods will
become more or less popular as techniques are refined, efficiency is fine-tuned, or new
technologies are developed.
Here, historically important discoveries for gene transfection and gene editing
methods are discussed, as well as method advantages and disadvantages. A timeline of
significant milestones in gene delivery and gene therapy is provided in Figure 1.

Figure 1. Significant milestones in gene delivery and gene therapy. Adeno-associated
virus (AAV), adenovirus (AV), cell-penetrating peptide (CPP), zinc finger nuclease
(ZFN), transcription activator-like effector nuclease (TALEN), clustered regularly
interspaced short palindromic repeats (CRISPR), CRISPR-associated protein 9 (Cas9).
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2. PHYSICAL METHODS

Physical methods of gene delivery act by directly penetrating or compromising
the cell membrane in order for nucleic acids to pass into cells. They are some of the
earliest methods of gene delivery, though cell viability and transfection efficiency for
many of the techniques is lacking. Physical methods are diagramed in Figure 2.

Physical Methods

Microiniection

Bioballistics

in vivo/in vitro

in vivo/in vitro

50-100% in cells [30]
slow/tedious
gle cells
precise
not im munogenic

3-15% in cells [35]
• low accuracy
• tissue damage
• high cost
• easy

Electroporation
in vivo/in vitro
20-40% in tissues [55, 56]
high cellular dam age/death
efficient
optimization for cell types

in vivo
40% in liver [41]
high volume/pressure
transfection iso ated
not immunogenic

Sonoporation
in vivo/in vitro
3% in cells [50]
cell lysis
tissue damage

Figure 2. Physical methods of gene delivery. The cell membrane is compromised by
different means in order to facilitate nucleic acid internalization. Microinjection,
bioballistics, hydrodynamic force, ultrasonic nebulization (a.k.a. sonoporation), and
electroporation are common physical delivery techniques.

2.1. MICROINJECTION
Microinjection, or the direct injection of genetic material into cells [22], was one
of the first methods used to transform cells. It is a simple method, but delicate and
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therefore difficult to carry out [23]. It does not rely on a carrier for DNA, making it not
immunogenic or toxic [24]. Nucleic acids are injected into a single cell using a needle.
DNA can then be localized to the nucleus after injection into the cytoplasm or be directly
injected into the nucleus to transform a cell. Microinjection is perfect for cloning and
single cell manipulation. The first cases of microinjection date back to 1911, when
Marshall Barber used the technique to clone bacteria [25]. The first animal clones were
created by transferring the whole nucleus of one embryonic frog cell to the oocyte of
another in 1952 [26]. However, the older the transplanted nuclei, the less likely a normal
tadpole was to develop. In 1974, microinjection was used to create the first transgenic
animal by injecting viral DNA into a mouse blastocyst [27]. In the 1990s, regional
transfection of tissue by DNA injection was demonstrated [18]. However, it was not until
1997 that adult cells were able to be used to create viable clones, resulting in the famous
Dolly the sheep [26, 28]. Using small amounts of DNA, the technique is cost effective
[29] . While efficiency is high when DNA is injected directly into the nucleus,
transformation can be low if DNA is degraded by cytoplasmic nucleases [23]. A mouse
cell line showed expression in 50 to 100% of cells given genes by direct nuclear injection
[30] . The process can be slow and tedious when many cells are to be transformed [22].
On the other hand, the method is not dependent on cell type, so it can be used with cells
that are difficult to transform [24]. Attentional benefits to this technique are the precise
control of the amount of genetic material passed to cells and the surety that most cells
treated will receive genetic material [31], with the nucleus receiving around 90% of fluid
directly injected [30]. More recent advances in microinjection techniques have led to the
development of devices used to inject multiple cells at once [32].
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2.2. BIOBALLISTICS
One forceful method of genetic transduction is bioballistics. In this technique, a
“gun” is used to accelerate metal particles covered in genetic material through cells [18].
Any particles that travel through the cells have a chance to leave behind the nucleic acids
that were on the surface of the metal. Tungsten, silver, and gold particles are most
commonly used as the carrier and are accelerated using pressurized inert gases or electric
charges [18, 33]. The size and speed of the particles play a major role in the gene transfer
efficiency [33]. Klein et al. first applied this method using plant cells in 1987 [18, 34].
The group used tungsten particles coated in nucleic acid and accelerated them using a
gunpowder blast [34]. A downside to bioballistics is that if a cell is hit with a large
number of particles, viability is reduced [34]. Low accuracy, tissue damage, and low
efficiency [35], in part due to high DNA degradation [36], are also issues. Only around 3
to 15% of cells targeted with bioballistic gene transfer show high expression [35]. The
cost of materials is also high [23], which can be a detriment to researchers if a large
number of transformations must be performed. However, the method is relatively easy to
carry out and stability of the carrier is not a concern [35]. The size and properties of the
metal particles also enable them to deliver multiple or large DNA molecules that other
methods may not [35]. A large concern from a toxicological perspective is that the
ultimate fate of the particles is often not known [37]. Metal particles may oxidize in
biological systems and result in unintended toxicity if they are not removed. Bioballistics
can be applied to both organisms and cells [23]. Advances in this method resulted in the
development of a hand-held gun, the Helios Gene Gun, which allowed in situ
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transformation more easily [36]. Xia et al. used the Helios Gene Gun to transfect the skin
and livers of mice with bioluminescent reporter genes [38].

2.3. HYDRODYNAMIC FORCE
Hydrodynamic force uses pressure in the circulatory system to increase the
permeability of cells [18]. The first successful application of hydrodynamic force for
gene delivery is attributed to Budker et al. in 1998 [39, 40]. This method was designed
for use in vivo, originally in rodents, but has been used in various animals including
rabbits, dogs, fish, pigs, monkeys, and humans [39]. Immunogenicity and toxicity of
carriers are not a concern as naked DNA is used in solution [41]. A solution around 8 to
12% of the subject’s body weight is injected quickly, in 5 to 7 seconds, to achieve the
systemic pressure needed to facilitate nucleic acid uptake [39, 41]. Transfection rate is
highly dependent on injection volume, injection time, and DNA concentration [41].
However, large injection volumes have been deemed unsafe for people [18] as too much
fluid in the circulatory system can lead to cardiac arrest [39]. Along with this, large
volumes of DNA may be difficult to cultivate for each individual injection. Due to the
need for a pressurized system, this method is not applicable to individual cells [39].
Transfection also often accumulates in specific organs, especially the liver [41, 42]. Lui
et al. showed that 40% of the hepatocytes of mice injected with plasmid DNA via the tail
vein expressed a reporter gene, while the lung, kidney, spleen, and heart all had
expression levels less than 1000-fold of the liver expression [41]. This makes the
technique particularly useful for gene expression in specific organs, but not useful if
expression is desired elsewhere. This method has been used to develop a mouse model of

14
hepatitis B infection, which normally is unable to infect rodents, by forcing viral
genomes into mice hepatocytes [39, 42, 43]. One technique used to decrease injection
volumes in animals larger than rodents is to use a balloon catheter to isolate a particular
organ so pressure can be increased locally [44]. When balloon catheters where used to
isolate the liver of pigs, injection volumes could be reduced from 10% to 1.25% of the
individual’s body weight [44]. This also allows organs and tissues with lower affinity for
transfection in whole body injections to be targeted.

2.4. ULTRASONIC NEBULIZATION
Fecheimer et al. were the first to demonstrate cells transfection using ultrasonic
nebulization, also known as sonoporation, in 1987 [45, 46]. This method relies on the
formation of pores in cell membranes by ultrasonic waves [33]. The intensity and
frequency of the ultrasonic waves used, as well as tissue type, determine the biological
effects [18]. Typically, ultrasound in the 2 to 20 MHz range, with maximum intensities
limited to 720 mW/cm2 by the US Food and Drug Administration (FDA) [47], is used for
medical imagining [48]. However, only 1 to 3 MHz, with higher intensities ranging from
0.5 to 2.5 W/cm2, are used for gene delivery [18]. Initial studies demonstrated
sonoporation using 20 kHz [48]. Ultrasound can result in heating and cavitation within
tissues, depending on the intensity of the waves [48]. Cavitation can concentrate
ultrasonic energy and occurs when ultrasound waves produce and interact with
microbubbles in solution, resulting in wave deflection, resonance frequency vibration of
bubbles, and bubble imploding [45, 48]. Cavitation of microbubbles causes mechanical
damage in cells and tissues, which can be observed as pore formation or cell lysis [48].
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The utilization of ultrasound in gene delivery was dramatically improved by combining
ultrasound wave application with injected microbubbles in the mid-1990s [18, 45]. The
addition of microbubbles “lowers the threshold for cavitation,” [45], as bubbles do not
need to be generated. Injected microbubbles are gas-filled vesicles with a shell that can
be composed of various substances, including phospholipids, proteins, and polymers [18],
and can vary between 1 to 10 pm in diameter [45]. Clinically, microbubbles are routinely
used as contrast agents for ultrasonic imaging [45]. During gene transfection, DNA can
be injected as a solution or integrated into microbubbles [33]. Ultrasound is applied to a
target location, limiting where cavitation occurs. Sonoporation has potential for in vivo
applications as it is noninvasive [45]. Ultrasound and site-injected phospholipid
microbubbles were able to successfully transfer a luciferase reporter gene into mouse
muscle tissue [49]. However, despite the potential applications, ultrasound has not been
applied for clinical gene therapy, due to low efficiency and high cell death [45]. Primary
rat cells treated with ultrasound only showed a 2.4% transient transfection rate and a
0.3% stable transfection rate, with only 50% of cells surviving the process [50].

2.5. ELECTROPORATION
It has been known that electricity alters membrane permeability since the 1960s
[18]. Electric fields can result in the formation of membrane pores, cell fusion, and cell
movement [51]. When electric pulses are applied to cells, the pores formed allow nucleic
acids to move across the plasma membrane [51]. The electric field causes the cell
membrane to polarize and breakdown temporarily [33]. Timing and intensity of the
electric pulses, as well as buffers, affect the delivery of nucleic acids [51].
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Electroporation parameters must be optimized for individual cell types because if the
intensity used is too high, cell membranes may not be able to close [51, 52]. Applying
electric pulses to cells can result in death, in part due to membranes no being able to seal
[22]. Different cell types are more effectively transformed with specific pulse length and
strength [33]. It can be time consuming to determine the best buffers and electric
intensity to use for various cell types [52]. However, the technique is useful for cells that
are hard to transform, such as T cells, hMSC, and HUVECs, and is efficient when low
cell viability is not a concern [51]. Electricity was first applied for genetic transformation
in 1982 in mouse lyoma cells by Neumann et al. [53], who coined term for
electroporation [51]. In 1991, the first in vivo transformation using electroporation was
demonstrated with mouse skin cells [18, 54]. In this process, a target location in the body
is injected with DNA. Electrodes are then used to apply pulses of electricity to induce cell
membrane permeability [18]. The efficiency is dependent on the distribution of the
electric field, which may be altered by electrode type and placement [51]. This method
has been demonstrated locally in the testis and eyes of mice and the forebrain of zebrafish
[51]. When DNA was directly injected into rat livers and treated with electric pulses, 30
to 40% of hepatocytes expressed a reporter gene [55]. Additionally, Heller et al. reported
that 20 to 30% of skin cells expressed a luciferase gene after transfection using
electroporation [56]. However, ability to access different organs noninvasively with
electrodes in vivo limits its applications [18].
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3. CHEMICAL AND BIOCHEMICAL METHODS

Chemical and biochemical methods of gene transfection involve complexing
nucleic acids with organic or inorganic compounds to facilitate cellular uptake.
Complexes interact with the cell surface and cell membrane molecules to induce
endocytosis or internalization. Chemical methods are diagramed in Figure 3.

Figure 3. Chemical methods of gene delivery. Chemical methods complex with nucleic
acids and mediate uptake by interacting with the cell membrane. Calcium phosphate co
precipitation, as well as peptide and lipid carriers, are commonly used chemical
transfection methods.

3.1. CALCIUM PHOSPHATE CO-PRECIPITATION
Calcium phosphate co-precipitation was first described by Frank Graham and A.J.
van der Eb in 1973 [22, 57]. This method utilizes the phosphates lining the backbone of
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nucleic acids. A stable ionic complex is formed between the backbone phosphates and
divalent metal cations, originally Ca2+ but Mg2+, Ba2+, and Mn2+ have also been used
in similar co-precipitations [58]. The ion-DNA phosphate complex can be endocytosed
by cells after coming in contact with the cell surface [22]. To form and precipitate
complexes, phosphate buffered saline is added to a mixture of DNA and calcium chloride
in solution [59]. Precipitates used for gene delivery usually range in size from 10 to 100
nm [59]. The method is relatively cheap, easy to carry out [24], and benefits from the
biodegradability of calcium phosphate [59]. It can be used with many cell types and is
often used when transfecting large numbers of cells [24]. However, cytotoxicity is a
concern as intracellular calcium levels are generally low [22, 59]. Increased intracellular
calcium levels could be a particular issue for muscle cell transfection, as calcium ions
regulate muscle contraction [60]. Ca2+ membrane pumps may be able to mitigate
calcium toxicity by pushing excess Ca2+ outside of cells [61]. Results from calcium
phosphate co-precipitation can be highly variable due to differences in complex size [22].
Transfection efficiency is controlled by the cell type and the precipitation conditions,
including calcium chloride and DNA concentration, pH, temperature, and crystal growth
time [59]. Smaller precipitates show higher transfection rates than larger particles [62].
As such, precipitates are not able to transfect cells if they are stored for long periods due
to nanocrystals growing into microcrystals [33, 59]. Jordan et al. demonstrated
transfection efficiencies of approximately 60% in CHO cells and approximately 40% in
HEK-293 cells using small particles, but efficiencies dropped to 3 to 5% when large
particles were used [63]. The variation in transfection efficiency between cell types is
also apparent, as transfection efficiency in neuronal cells is generally low, ranging from 1
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to 5% [64]. Efficiency variation and low reproducibility may be due to rapid nucleation
and growth of the particles [61]. This method is difficult to apply in vivo [22, 58], in part
due to “poor colloidal stability and uncontrolled growth” [61]. However, calcium
phosphate precipitates modified with polymer and lipid coatings have shown promise for
in vivo delivery [61]. Roy et al. modified calcium phosphate precipitates with a polymer
and a targeting ligand to increase gene delivery to liver cells in mice by 400 to 500%
compared to unmodified particles [58].

3.2. LIPOFECTION
Gene transfection using lipids, also called lipofection, is one of the most used
nonviral methods for genetic transfer [18]. Lipofection was developed and first
demonstrated by Felgner et al. in 1987 [52, 65]. A variety of lipids are used in lipofection
but most are cationic and amphiphilic, generally being composed of a hydrophilic amine
head, linker, and hydrophobic hydrocarbon tail [66]. These lipids form micelles and
liposomes when placed in aqueous solutions, with hydrophobic tails associating together
and hydrophilic heads interacting with the environment [66]. Negatively charged DNA
can be electrostatically complexed to the positively charged anime head of the lipids; the
complexes are often referred to as lipoplexes [66]. DNA is protected from nucleases in
the lipoplex as the nucleic acid becomes surrounded in lipids [18]. Additionally,
positively charged heads are able to interact with the negatively charged cell membrane
molecules, such as proteoglycans and glycoproteins, mediating internalization [18].
Lipoplexes can be endocytosed or can merge into the cell membrane, depending on the
properties of the lipids and cells used [67]. Since lipids are basic components of cell
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membranes, lipofection is nonimmunogenic [66]. The lipids are easily modified to
improve efficiency [66]. “Helper” lipids, such as dioleoylphosphatidylethanolamine
(DOPE) or cholesterol, can be included in the lipoplex mixture to improve gene delivery
[66]. Lipid composition and the ratios of helper lipids can be optimized to improve
efficiency for specific cell lines [19]. Functional groups, such as polyethylene glycol
(PEG), may also be added [66]. Transfection efficiency is influenced greatly by the size
of the lipoplex [68]. Larger lipoplexes are more efficient at delivering DNA in vitro [69].
However, larger lipoplexes are cleared from the blood faster than smaller ones in vivo
[68]. The type of lipids used, lipid and DNA concentration, and transfection media also
affect delivery efficiency [69]. One of the most commonly used and commercially
available lipids for transfection is lipofectamine [19, 70, 71]. Using Lipofectamine®
2000, Dalby et al. showed transfection in 20 to 30% of primary rat neurons [70].
However, lipofectamine and other lipoplexes can be toxic. For example, lipofectamine
and several lipoplexes containing helper lipids reduced the viability of A549 and H1299
cells by around 20% [71]. Kulkarni et al. treated primary chicken embryonic cells with
lipofectamine and saw only 33% cell survival, with around a 50% transfection rate [19].
The group was able to increase survival to 85% and transfection to 90% in the same cells
by modifying the ratios and composition of the lipids used.

3.3. CELL-PENETRATING PEPTIDES (CPPs)
3.3.1. Introduction to CPPs. CPPs, also known as protein transduction domains
(PTDs), Trojan peptides, or membrane transduction peptides, are short peptides generally
containing 5 to 30 amino acids [17, 72-75]. They are characterized by their remarkable
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ability to translocate through plasma membranes and enter into cells, tissues, and even
organisms [76, 77]. CPPs possess the ability to traverse biological membranes efficiently
in a process termed protein transduction [78]. Importantly, CPPs are capable of
transporting numerous cargo molecules, such as DNA, RNA, oligonucleotides,
liposomes, proteins, and nanoparticles, both in vitro and in vivo [73, 76, 77].
CPPs have very different origins and are ambiguous in many ways [17]. CPPs
may originate from naturally occurring peptides in living organisms, chimeric peptides
from naturally modified proteins, and synthetic peptides from design [73]. Many early
CPPs were identified from naturally occurring protein sequences that were found to
possess membrane-translocating properties. The first protein discovered to translocate
into the nucleus was the HIV-1 transcription-transactivating (Tat) protein, demonstrated
by Frankel and Pabo in 1988, with the minimal sequence being isolated in 1997 [79].
Penetratin, a 16-residue CPP isolated from the Drosophila Antennapedia (ANTP)
homeodomain, was discovered in 1994 [79]. Protein/peptide engineering has developed a
combination of domains with different properties to generate chimeric CPPs.
Subsequently, growing knowledge based on the identified properties of CPPs has led to
the development of novel CPPs with completely designed sequences. Based on their
physicochemical properties, CPPs may be classified as cationic peptides with positively
charged surfaces, hydrophobic peptides with high hydrophobic amino acid content, or
amphipathic peptides with both hydrophobic and hydrophilic fragments [73]. As
summarized in Table 1, independent of CPP origin or classification, several algorithms
have recently been built to allow for prediction of amino acid sequences that potentially
have translocating properties [80-91].
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Intracellular delivery of various cargos is mediated by binding to CPPs either
covalently or noncovalently [17, 72, 76]. CPPs can be directly attached to their cargo
molecules through covalent linkage, termed covalent protein transduction (CPT).
However, CPT involves relatively expensive and labor-intensive synthesis, and may not
be suitable for the delivery of nucleic acids and nanoparticles. Noncovalent protein
transduction (NPT) utilizes noncovalent association, such as electrostatic interactions and
hydrophobic effects, between CPPs and cargo molecules. The major advantages of NPT
over CPT are simplicity of preparation, cargo versatility, and low working
concentrations, which possibly contribute to reduced toxicity. However, NPT may suffer
from premature dissociation of cargos from CPPs and off-target effects within cells due
to the relatively weak interacting forces between CPPs and cargos.

Table 1. Predictors of cell-penetrating peptides.
N am e
CPPsite 2.0
CPPpred
K E L M -C PPpred
CellPPD
C2Pred
CPPred-RF
SkipC PP-Pred
M L C PP
C PPred-FL
G -D ipC
StackC PPred
T argetC PP

W ebsite

R eference

http://crdd.osdd.net/raghava/cppsite/
http://biow are.ucd.ie/~com pass/biow arew eb/S erver pages/cpppred.php
http://sairam .people.iitgn.ac.in/K E L M -C P Ppred.htm l
http://crdd.osdd.net/raghava/cellppd/subm ission.php
http://lin-group.cn/server/C 2Pred
http://server.m alab.cn/C PPred-R F/
http://server.m alab.cn/S kipC PP-Pred/Index.htm l
http://w w w .thegleelab.org/M L C PPE xam ple.htm l
http://server.m alab.cn/C PPred-FL /
N /A
https://github.com /E xcelsior511/StackCPPred
N /A

1801

ML
[8 2 1
I83L
1811

ML
ML
ML
M L

ML
I9 0 1
M L

N/A: not availab e

3.3.2. Mechanisms of CPP Action. Due to their inherent ability to cross plasma
membranes, CPPs have been employed extensively to facilitate the transport of cargo
molecules into cells. However, the detailed cellular uptake mechanism of CPPs is not

23
well understood. Generally, it is accepted now that CPPs and CPP-cargo complexes are
predominantly internalized into cells by two main pathways: endocytosis and direct
translocation [17, 76, 77, 92]. However, the exact cellular uptake mechanism of CPPs and
CPP-cargo complexes is determined by numerous factors, such as the amino acid
sequences of CPPs (hydrophobicity and net charge), extracellular concentration of CPPs,
cargo properties, cell type, and the assay temperature [92]. No matter what mechanism,
the electrostatic interactions between the positively charged residues of CPPs and
negatively charged glycosaminoglycans, especially heparan sulfate proteoglycans, of the
membrane are the first crucial step for cellular uptake of CPPs and CPP-cargo complexes
[92].
Endocytosis is a natural and energy-dependent process, occurring in almost all
cells by direct interaction with the plasma membrane or by electrostatic interactions with
cell surface proteoglycans [76, 92]. Endocytosis can be classified as phagocytosis (cell
eating) or pinocytosis (cell drinking) [76]. Different types of pinocytosis include
macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated endocytosis, and
clathrin- and caveolae-independent endocytosis [93]. The internalization mechanism for
CPP-cargo complexes may involve a combination of specific pathways [76]. Moreover,
several endocytic pathways can be used in parallel, or alternative pathways can
compensate for the inhibition of specific pathways [17].
Direct translocation, also known as direct membrane penetration, is an energyindependent process where CPPs and CPP-cargo complexes directly penetrate through
cellular membranes [76]. This direct translocation model involves a passive membrane
diffusive or destabilization process that does not require binding to proteinaceous cell
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surface receptors. Direct physical interaction between the cationic residues of CPPs and
the anionic phospholipids of the plasma membrane leads to direct membrane penetration
[17]. Direct translocation usually completes in a short timescale, as little as 5 minutes.
Energy-independent internalization of CPP-cargo complexes can be observed by
incubating cells at low temperatures (4°C), since low temperature treatment seizes all
energy-dependent movement across the cell membrane. CPP-cargo complexes that
directly penetrate the membrane have similar uptake at 4 or 37°C [17]. So far, the
mechanism of direct translocation can be explained by three main models: the inverted
cell model, the pore formation model, and the carpet model [92].
3.3.3.

Applications of CPPs in Clinical and Gene Therapies. Today, there is

an urgent need to develop new therapeutic agents. Many conventional treatments are
outdated and less desirable due to drug resistance, low selectivity, and poor solubility
[74]. Therapeutic peptides are a promising and novel approach to treat many diseases,
including cancer and genetic disorders. Therapeutic peptides have several advantages
over proteins or antibodies, as they are easy to synthesize, have high target specificity as
well as selectivity, and have low toxicity. Nevertheless, therapeutic peptides do have
significant drawbacks related to their stability and short half-life [74].
In 1995, one of the earliest examples of a CPP used in gene therapy was
demonstrated. The ANTP CPP was covalently linked to an antisense DNA of amyloid
precursor protein (APP), which gave the antisense treatment direct access to the cell
cytosol and nucleus [78, 94]. Internalized antisense oligonucleotides mediated by ANTP
decreased APP protein expression, resulting in the inhibition of neurite outgrowth [94].
Later, in 1997 the first noncovalent delivery of oligonucleotides was demonstrated using
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MPG, a 27-residue chimeric CPP [79, 95]. Kardani et al. demonstrated reporter gene
expression in 25 to 55% of mammalian cells transfected with CPPs [96]. Accordingly,
numerous CPPs have been reported to assemble antisense oligonucleotides, small
interfering RNA (siRNA), or plasmid DNA into CPP-cargo nanoparticles, possessing
positive charges that allow them to interact with cellular membranes and to internalize
into cells [73, 97, 98].
In vivo delivery of nucleic acids is a challenge that has to be solved before gene
therapeutic applications can be translated into the clinics [99]. Preferably, the delivery
should be applicable for systemic administration, because this has the potential to reach
all corners of the body. Despite intensive research over the last 20 years, only a few gene
therapeutic vectors have been approved for the use in clinics [100]. Many clinic studies
have revealed safety issues along with inefficiency problems. In 2012, the first
statistically significant clinical trial opened the door for clinical delivery of
macromolecular therapeutics [101]. Subsequently, there were over 25 clinical trials
performed predominantly using CPPs in 2015 [102], and many pre-clinical and clinical
trials with CPP-derived therapeutics were conducted in 2017 [103].
In addition to positive or negative regulation of gene products, CPPs may be used
for the delivery of genome editing tools [73, 98, 104, 105]. In fact, an innovative
application of CPP-mediated delivery of the CRISPR-Cas9 system in genome editing was
reported in 2014 [106]. Both covalent conjugation of Cas9-CPP by a thioether bond and
noncovalent CPP/single-guide RNA (sgRNA) complexing led to efficient gene
disruptions in several human cell types with low off-target incision effects. This study
demonstrated CPP-enabled direct delivery of both recombinant Cas9 protein and sgRNA
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into cultured mammalian cells [98, 105]. However, the genome editing frequency of this
Cas9-CPP and CPP/sgRNA treatment tended to be low (less than 15% after three rounds
of treatment) [107].
Collectively, CPPs have long been regarded as promising therapeutic delivery
vehicles, not only because of their high internalization ability but also their potential for
modification [92]. As promising carriers, CPPs generally have several advantages, such
as low cytotoxicity, ease of preparation, and a wide variety of cargo type compatibility
[74, 92, 108]. However, there are still shortcomings for drug delivery in vivo, such as
cell-free specificity, short duration of action, and lack of oral bioavailability [74, 92,
108].

4. VIRAL METHODS

The goal of any virus is to infect and exploit host cells by injecting nucleic acids
into their cytoplasm and taking over the host’s cellular machinery. The life-cycle of a
virus makes them a particularly promising carrier for gene therapeutics. However, for
safety reasons, viral and retroviral vectors have to be modified to reduce their
immunogenicity and cytotoxicity. Modification usually involves deletion or truncation of
viral genes necessary for viral replication. Currently, viruses used as vectors for nucleic
acid delivery have recombinant, replication-defective genomes that have had therapeutic
genes added into them. Often, helper vectors or viruses are used to package the
replication-defective viruses that carry therapeutic genes, which reduces the chance for
viruses to gain competency. In the below sections, applications, advantages, and
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disadvantages of viral and retroviral vectors as carrier platforms are discussed. Viral
delivery methods are diagramed in Figure 4.

Figure 4. Viral methods of gene delivery. Viral vectors vary in particle size, genome size
and type, transgene capacity, capsid geometry, and whether they have an envelope or not.
Vectors enter either by endocytosis or through membrane fusion. Integration of delivered
nucleic acids into the host genome is dependent on the virus type.

4.1. ADENOVIRUS (AV) VECTORS
Adenoviruses (AVs) were first isolated from human adenoid tissue in 1953 [109].
These viruses were the first viruses used for gene therapy in the 1990s and later they
began to be tested in clinical trials [109]. In 1993, the first in vivo human gene therapy
was performed in a cystic fibrosis patient using a recombinant AV vector [110, 111].
However, sufficient precautions were not taken with this early vector and later trials led
to the death of Jesse Gelsinger in 1999 [14].
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Adenoviruses are non-enveloped viruses with icosahedral capsids ranging from
60 to 90 nm in size. They contain a linear, double-stranded DNA genome of 30 to 40 kb
and enter host cells by clathrin-mediated endocytosis [112]. The genome of adenoviruses
includes various transcriptional units, which can be categorized based on when they are
transcribed [6]. The units are early genes (E1A, E1B, E2, E3, and E4), delayed early (IX
and Iva2), major late (ML), and late genes used in post-translational processing (L1, L2,
L3, L4, and L5) [6]. The E1 region and a portion of E3 region in the AV genome were
eliminated in the first-generation of recombinant AVs in order to accommodate a
transgene. In addition to the potential of gaining replication competency in packaging cell
lines, recombinant AVs tend to elicit a powerful immune response and cytotoxicity. To
alleviate these undesired outcomes, vectors were further modified in a second generation
where the E2 and E4 regions, which are responsible for immune reactions, were deleted
[113, 114]. This also allowed the transgene packaging capacity of the vectors to increase
from 5 kb to 14 kb. Further manipulations to produce a third generation of AV vectors
nearly depleted the entire AV genome while allowing it to accommodate up to 37 kb
target genes for delivery [115]. Genome components crucial for viral DNA replication
and packaging were retained [6]. The onset of expression can occur as early as 16 to 24
hours after infection.
Adenoviral DNA cannot integrate into the genome and is unable to replicate
during cell division, which imposes limitations for broader gene therapy; on the other
hand, this eliminates the possibility of chromosomal rearrangements that could lead to
potential tumor formation [116]. One group showed gene transduction efficiencies of 55
to 93% after using 4 different adenoviral vectors to infect CD34+ cord blood cells in vitro
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[117]. Their highly efficient transduction of most tissue, high levels of protein
expression, and transient gene expression make them attractive in gene transfer and
therapy [118]. Including trials up to 2017, 20.5% of gene therapy trials used adenoviral
vectors [21].

4.2. ADENO-ASSOCIATED VIRUS (AAV) VECTORS
Adeno-associated virus (AAV) was discovered in the mid-1960s when scientists
were studying adenovirus and later identified AAVs in human tissues [119, 120]. A
journey of 20 years to understand AAV biology eventually yielded the first AAV vector
used for in vitro gene delivery in 1984. The first human test of AAV vectors was to treat
a patient with cystic fibrosis in 1995 [121]. In 2012, the European Medicine Agency
approved the first AAV vector-based gene therapy drug to treat lipoprotein lipase
deficiency.
Adeno-associated viruses are non-enveloped, single-stranded DNA viruses with
4.7 kb genomes that are encapsulated in icosahedral capsids 18 to 25 nm in diameter.
Wild-type AAVs require a helper virus to complete their life cycle. The non-pathogenic
nature and the ability to package various transgenes make AAVs an ideal vehicle for gene
therapy [121, 122]. AAVs are internalized by endocytosis mediated by clathrin [6]. The
genome of the most commonly used serotype, AAV2, contains genes that encode
regulatory Rep proteins and structural Cap proteins. The former carry out genome
excision from the host chromosome, replication, packaging, and integration whereas the
latter produce capsid proteins. Inverted terminal repeats flanking the genome possess
regulatory cis-acting sequences needed for the virus to complete its life cycle and for
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integration into the host genome. In making AAV vectors, Rep and Cap were removed
from AAV DNA to make room for therapeutic genes. Required proteins are provided to
the virus by helper vectors during vector production [123]. An example of vector
production in HEK293 cells would involve the functions of Rep and Cap being supplied
in a separate helper vector, with an additional helper vector containing the E4, E2a, and
VA regions required for replication [123].
The primary disadvantages of AAV vectors are that delivery is limited to smaller
sized genes of interest (less than 5.0 kb of DNA), a slower onset of expression (2 to 7
days for in vitro and 3 to 21 days for in vivo), and relatively low levels of protein
expression that leads to a necessity to re-administration AAV vectors. Another significant
drawback of AAVs is that they often trigger immune responses. For instance, neutralizing
antibodies lead to rapid clearance of AAVs from the circulatory system by opsonizing
viral particles and thus facilitate uptake by phagocytic cells. To overcome this issue,
certain strategies have been employed that include re-engineering AAV vectors, use of
capsid decoys, changing the route of administration, plasmapheresis, disruption of B cell
activation and reduction of the number of activated B cells, and targeting T cell
activation. Each method has disease-dependent pros and cons [124].
Currently more than nine different serotypes of AAV vectors have been used in
clinical trials. The infectivity of AAVs in different cell types can be increased by utilizing
different serotypes. Liver, eye, heart, muscle, brain, and bone have been targeted for
therapy. Most of these trials are in phase I and/or II, while only a few have entered phase
III. Around 7.9% of gene therapy clinical trials used AAV vectors up until 2017 [21]. The
transduction of AAV vectors is rate-limited by the necessity for AAV single-stranded
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DNA to be converted to double-stranded DNA before transcription [121]. It was
demonstrated that an AAV alone was only able to transduce approximately 5 to 20% of
HEK293T or HepG2 cells [125]. However, this has been improved by using methods,
such as self-complementary vectors, to overcome the rate-limiting step [126].

4.3. RETROVIRAL VECTORS
Retroviruses are enveloped viruses with two identical copies of single-stranded
RNA that range in length from 7 to 10 kb [127-130]. The entire viral particle is about 100
to 200 nm. Retroviruses are classified as simple retroviruses or complex retroviruses
according to their genomic organization and biological features. Gamma-retroviruses and
lentiviruses are representative simple retroviruses and complex retroviruses, respectively.
All retroviruses enter into cells either by receptor-mediated endocytosis or membrane
fusion [131, 132]. The unique features of retroviruses lie in their capability to reverse
transcribe their RNA into complementary DNA (cDNA) via reverse transcriptase activity
and to integrate the cDNA into the host genome via integrase activity. The integration
allows for hijacking the host’s replication machinery for viral reproduction for further
infection. In the below sections, two major types of retroviral vectors for gene therapy are
discussed.
4.3.1. Gamma-Retroviral Vectors. Gamma-retrovirus possesses a simple
genome structure. The gag gene encodes structural proteins and proteins pertaining to the
budding process. The pol gene codes for a protease, a reverse transcriptase, and an
integrase. The protease cleaves the gag polyprotein. The reverse transcriptase is needed
for the generation of viral cDNA from viral RNA and the integrase aids integration of
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viral cDNA into the host cell genome. All regulatory elements involved in viral RNA
processing lie in the long terminal repeat (LTR) regions of viral genome.
The most commonly used retroviral vector for gene therapy was derived from
murine leukemia virus (MLV), which is a simple gamma-retrovirus [132] with a nearly
spherical capsid [133]. The first ex vivo gene therapy trial was approved in 1990 by the
FDA. This trial treated the white blood cells of two young adenosine deaminase
deficiency patients with a modified MLV vector carrying a normal gene [134, 135]. The
efficiency of the therapy was debated [134]. Throughout decades, safety considerations
have directed the evolution and development of the MLV vector system. The goal of
manipulating vector arrangement was to remove its replication competence. The most
advanced third generational gamma-retroviral vectors utilize a split-genome approach
comprised of three plasmids. The main retroviral vector contains the LTR, a primer
binding site for reverse transcription, and the packaging signal, as well as the transgene
which can be up to 8 kb long. The structural and enzymatic retroviral genes are located in
two helper plasmids. The gag, pol, and env genes in the helper plasmids do not contain
retroviral elements pertaining to packaging, thereby reducing the probability of
recombination [132]. To further improve safety, self-inactivating (SIN) vectors were
developed by making the 3’-LTR nonfunctional. Even with so many modifications, once
genes are delivered to cells, insertional mutagenesis, enhancer interaction, or premature
termination may occur, which can lead to severe side effects.
Gamma-retroviral vectors have been used to transfer genes to hematopoietic stem
cells to correct blood-related genetic disorders and skin diseases, such as Wiskott-Aldrich
Syndrome, SCID-X1, SCID-ADA, epidermolysis bullosa, and melanoma [11, 136-143].
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In an ex vivo trial using gamma-retroviruses to treat SCID-X1, Gaspar et al.
demonstrated an approximate 68% transfection efficiency in CD34+ bone-marrow stem
cells [140]. Currently, approximately 17.9% of gene therapy clinical trials use retroviral
vectors [21]. However, treating patients with integrating viruses is risky as integration has
been associated with mutagenesis and oncogenesis when normal genes are disrupted or
onco-genes are activated. For instance, in one trial of nine SCID-X1 patients, four
patients treated with gamma-retroviral vectors developed T cell leukemia after gene
therapy [136, 139].
4.3.2. Lentiviral (LV) Vectors. Lentivirus (LV) vectors are derived from HIV-1.
They were first used in clinical trials in 2003 to deliver an antisense sequence for the
HIV-1 envelope gene to CD4+ cells ex vivo [144]. In addition to gag, pol, and env found
in gamma-retroviruses, the HIV-1 virus contains two regulatory genes, tat and rev, that
are essential for replication. Tat and rev regulate trans-activation of gene expression and
nuclear export of mRNAs. Importantly, HIV-1 contains four accessory genes that encode
critical virulence factors for virus transmission enhancement. The lentiviral capsid is
cone-shaped, rather than spherical [133]. In order for HIV-1 to be used safely in gene
therapy, significant modifications to its genome were carried out [145].
The first generation of lentiviral vectors consisted of a major portion of the HIV
genome, including retention of the gag and pol genes. The envelope protein (env) was
supplied by another virus called VSV-G, which broadened the range of mammalian cells
that could be transduced. The second generation took out accessory virulence genes, such
as vif, vpr, vpu, and nef, without compromising transduction efficiency. The third
generation of lentiviral vector systems underwent significant genome rearrangement and
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contained four plasmids: a vector plasmid, two packaging plasmids (containing gag, pol,
and rev separately), and one envelope plasmid (containing env from VSV-G). The splitgenome approach was intended to maximize the segregation of cis- and trans-acting
functions and to minimize the possibility of homologous recombination events in order to
reduce the generation of replication-competent lentiviruses. The removal of all accessory
genes in the vector plasmid achieved a higher safety level. The gene tat was replaced by a
modified LTR with a constitutively active promoter sequence [146]. The LTR sequence
was further modified to become self-inactivating (i.e., SIN 5’ and 3’ LTR) [131]. To
enhance viral titers and transgene expression, central polypurine tract/central termination
sequence (cPPT/CTS), an enhanced promoter, and a woodchuck hepatitis virus
posttranscriptional regulatory element were included [123]. Similar to gamma-retroviral
vectors, lentiviral vectors can deliver transgenes up to 8 kb in length [67].
The most distinctive advantage of LVs over other retroviral vectors is their ability
to penetrate the nuclear envelope of non-dividing cells. This extraordinary characteristic
allows lentiviral vectors to be used in neurons and other non-dividing cells in adult
organisms [147]. In addition, lentiviral gene therapies have been used in vascular
transplantation, chronic granulomatous diseases, prostate cancer, heamophillia A,
rheumatoid arthritis, and diabetes mellitus [148-151]. In the past decade, the clinical use
of LVs has gained significant traction in gene transfer into CD34+ hematopoietic stem
cells (HSC) to treat a variety of genetic disorders, such as P-thalassemia, X-linked
adrenoleukodystrophy, metachromatic leukodystrophy, and Wiskott-Aldrich Syndrome
[10, 12, 13, 152, 153]. Ex vivo transduction of HSCs with a lentiviral vector to treat
Wiskott-Aldrich Syndrome resulted in 88 to 100% gene transfer efficiencies in CD34+
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bone-marrow stem cells [10]. Approximately 7.3% of gene therapy clinical trials utilized
lentiviral vectors up until 2017 [21].

5. GENOME EDITING

Zinc finger nucleases (ZFNs), transcription activator-like effector nucleases
(TALENs), and CRISPR systems recognize and cut DNA sequences and have been
utilized for genome editing [1]. ZFNs, TALENs, and CRISPR systems function through a
DNA-targeting domain and a non-specific nuclease domain, resulting in a double strand
break (DSB) in the DNA at the target site. The DNA-targeting domain is unique to each
system, but the cleavage and cellular repair of a break are similar.
After a double-stranded DNA break in a eukaryotic cell, the conserved homologydirected repair (HDR) or non-homologous end joining (NHEJ) pathways are used to
repair the gap [154]. NHEJ repairs the DNA break by quickly ligating the strands;
however, it is not accurate and frequently results in short insertions and/or deletions that
generate loss-of-function mutations [154, 155]. This may be desirable if gene inactivation
is the goal. NHEJ-mediated repair is dominant in cells in the G0 and G1 phases of the cell
cycle [156]. In HDR, a strand of template DNA similar to the breakage site is used to
repair the gene [154, 155]. Homologous DNA with corrected bases can be delivered with
gene editing tools and used as a template to fix the gene or add in a new gene [154].
However, HDR is restricted to cells in the S and G2 phases of the cell cycle [156].
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Figure 5. Genome editing techniques. All methods function by causing double strand
breaks in DNA at targeted sequences. Cells repair the damage through non-homologous
end joining (NHEJ) or homology-directed repair (HDR). ZFNs and TALENs share the
same endonuclease (FokI) to induce breaks but target sequences using either zinc finger
(ZF) or transcription activator-like effector (TALE) protein subunits. CRISPR uses a Cas
endonuclease and targets DNA with a single-guide RNA (sgRNA).

ZFNs and TALENs rely on proteins to specifically interact with DNA sequences
and CRISPR systems use a RNA guide sequence [1, 157]. The use of RNA for targeting
makes CRISPR-Cas9 systems easier to manipulate than ZFNs and TALENs as proteins
must be engineered to bind new DNA sequences [157]. The rate of mutations induced by
these systems varies, with ZFNs having low success rates ranging from 0 to 19% [158],
TALENs ranging from about 2 to 56% [159], and CRISPR ranging from approximately 2
to 80% [160]. CRISPR systems have emerged as the front-runner for genome editing due
to higher success rates and simpler target alteration. However, in order to function,
editing tools need to be delivered into cells [1]. Some of the above methods may be used,
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but the safety and efficiency of these delivery systems still need to be considered.
Genome editing techniques are diagramed in Figure 5.

5.1. ZINC FINGER NUCLEASES (ZFNs)
Zinc finger nucleases (ZFNs) are site-specific endonucleases that induce double
strand breaks in DNA [154]. They can be designed to target specific DNA sequences.
ZFNs are zinc finger proteins, a type of eukaryotic transcription factor, linked to a FokI
restriction enzyme nuclease domain, which is of bacterial origin [154, 161]. The zinc
finger proteins provide specificity and the restriction enzyme enables the DNA to be cut
[154]. Both segments can be modified individually for optimization and then joined. The
combination of modular DNA sequence-specific proteins and the non-specific FokI
nuclease domain was first developed in 1996 [157, 161], with initial applications
demonstrated in mammalian cells and Drosophila [157]. ZFNs have been used to target
gene sequences in CHO cells, human cells, Drosophila, zebrafish, tobacco plants, and
nematodes [155].
Zinc fingers proteins are very diverse in nature and very few residues are
conserved between them [162]. They often contain cysteine and histidine amino acids
that provide essential interactions with a zinc ion, which stabilizes the folding of the
protein [162, 163]. Zinc fingers containing two cysteines and two histidines (Cys2-His2)
play roles in protein interactions with DNA, RNA, and other proteins [162] and many are
transcription factors [163]. Zinc fingers used in ZFNs are of this type [154]. Cys2-His2
zinc fingers often fold into a two-stranded antiparallel P-sheet and an a-helix, which bind
around the zinc ion [162]. Generally, the cys residues are located at one end of one P-
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sheet and the his residues are in the a-helix C-terminal area, with variable spacing. Loss
of function results from alteration of the either the cys or his residues, indicating their
essential role. The fingers in a protein are linked with a spacer sequence that influences
“the spacing of the fingers along the DNA site” and is important for DNA binding
affinity [162]. When binding DNA, the protein wraps around the helix, with each a-helix
of individual fingers interacting with the major groove. The residues along the surface of
the finger’s a-helix seem to be responsible for base-specific interactions [162, 163].
Finger proteins also interact with the phosphate backbone of the same DNA strand base
interactions are made with, further securing the protein [162].
The FokI domain is only functional as a dimer, formed by two separate ZFNs
binding DNA and orienting their nuclease monomers into the proper orientation [154].
Each finger binds specifically to about 3 DNA base pairs, with early studies incorporating
3 fingers and more recent ones using up to 6 per monomer, allowing 18 to 36 base pairs
to be recognized with the dimer [154]. Libraries of zinc fingers have been assembled that
specifically bind combinations of the three base pair sequence, allowing zinc fingers to be
selected and bound sequentially in order to target the desired DNA sequence [164]. Using
different combinations of fingers in the set of dimers allows for longer sequences to be
targeted [154]. However, designing ZFNs with sequence-specificity can be difficult
because combining natural and synthetic fingers modularly can result in unforeseen
interactions between other fingers and DNA bases [154]. Engineering new synthetic
fingers can be complex [1].
Off-targeting is a major concern with ZFNs. Fingers may bind to and cut similar
sequences in the genome, other than the one intended [154]. If two different ZFNs are
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paired together to target a sequence, off-targeting may also occur because homodimers
can form. However, this particular issue has been resolved by developing ZFNs that only
function as heterodimers [154, 165]. ZFNs can also be toxic, likely due to off-targeting,
with only 20 to 60% of 293T cells surviving transfection with ZFN plasmids [166]. ZFNs
may not efficiently break a sequence if chromatin structure is too dense, due to the
necessity of the protein fingers wrapping around the DNA helix [154]. ZFNs have not
been used extensively since their development because of the complexity in designing
fingers to target new sequences and the difficulty in validating binding [157].

5.2. TRANSCRIPTION ACTIVACTOR-LIKE EFFECTOR NUCLEASES
(TALENS)
Similar to ZFNs, transcription activator-like effector nucleases (TALENs) cause
double strand breaks in DNA using a FokI nuclease domain joined with a DNA-targeting
domain [167, 168]. TALENs were created in 2010 [169, 170], originally with FokI
because the targeting domain was inserted into the same plasmid used to create ZFNs
[171].
The DNA targeting domain of TALENs, transcription activator-like effectors
(TALEs), were discovered in Xanthomonas, a genus of bacterial plant pathogens [171].
TALEs mimic eukaryotic transcription factors and are secreted by the bacteria to weaken
plant cells, making them more vulnerable to attack after their gene transcription is
altered. TALEs can be engineered for DNA binding specificity [168]. Since their
discovery, TALENs have been applied in a variety of cells and organisms, including
yeast, Drosophila, human cell lines, zebrafish, frogs, rice, and roundworms [168].
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The potential of TALEs for DNA targeting is greater than zinc fingers. Individual
TALE subunits can be modularly combined in order to produce a sequence-specific
binding protein [164]. TALE subunits are composed of a highly conserved amino acid
sequence ranging from 33 to 35 residues long and were discovered because of their
repeating sequence [168]. TALE repeats in the natural protein are flanked by amino- and
carboxy-domains, which are also incorporated into TALENs. Each subunit in a TALE
array binds one nucleotide. Hypervariable residues at positions 12 and 13 are responsible
for base-specificity [171]. Multiple of these diresidues can bind the same base with
varying efficiency. The most common diresidues used in research to bind the DNA bases
A, T, G, and C are the amino acid pairs NI, NG, NN, and HD, respectively; however, NN
has also been shown to bind A so NH and NK have been implemented to decrease offtargeting [171]. The conserved amino acids in each monomer fold into a-helices on either
side of the hypervariable residues, forming a v-shape [168]. These v-shaped subunits fit
into the DNA major-groove so that their diresidues make contact with the bases and
together wrap around the DNA to form a superhelix [168].
Due to the use of FokI, TALENs also function in pairs [171]. Targeting domains
are designed to bind to opposite DNA strands with 12 to 25 base pair spacing between the
binding points. TALENs are often created to target 18 or more base pair sequences,
though specificity may decrease with longer chains [167]. TALENs have lower toxicity
and higher specificity than ZFNs [165]. Production and validation of TALENs is also
easier [157]. However, off-targeting may still be a concern and they are much larger than
ZFNs, making them more difficult to deliver to cells as many delivery methods have
limits to cargo size [165]. Although, off-targeting seems to be less when TALENs are
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used to target the same genes as ZFNs [167]. Each pair of TALENs still must be
engineered when a new DNA sequence is to be targeted [169], which may have
contributed to their limited application [157]. Regular use of TALENs may have also
been hampered by the discovery of CRISPR-Cas9 shortly after they were developed.

5.3. CRISPR-CAS SYSTEMS
5.3.1. Development History. The CRISPR-Cas system was derived from an
adaptive immune system of bacterial defense against foreign invaders, such as viruses,
phages, and certain plasmids. In 1987, clusters of short palindromic DNA repeats
separated by hypervariable spacer sequences were discovered in Escherichia coli [172]. It
was revealed that the bacteria captured DNA segments from invading viruses or foreign
DNA, and used them to create DNA repeats, termed clustered regularly interspaced short
palindromic repeats (CRISPR) in 2002 [173]. These CRISPR allow the bacteria to retain
a history of previous viral infections or transformed DNA in the bacterial genome. When
the viruses or closely related ones attack again, the bacteria produce RNA segments
transcribed from these CRISPR to target the invasive genetic material, similar to current
uses of iRNA. CRISPR-associated (Cas) genes are usually located adjacent to each
CRISPR locus and code for a variety of polymerases, nucleases (both DNA and RNA),
helicases, and RNA-binding proteins. The bacteria use Cas9 or a similar enzyme to cut
foreign DNA apart, which disables the viruses or destroys other harmful DNA.
In 2012, two research teams first developed the CRISPR-Cas9 system for genome
editing based on the bacterial defense system [174-177]. As summarized in Table 2, the
original developers have launched their own biotechnology companies. They shared the
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2016 Tang Prize in Biopharmaceutical Science for their work in "the development of
CRISPR/Cas9 as a breakthrough genome editing platform that promises to revolutionize
biomedical research and disease treatment" [178]. They were also winners of the Canada
Gairdner International Award in 2016. This genome editing approach has inarguably
revolutionized the field of molecular biology and medical research, and has had a
profound and rapid impact on the development of more effective strategies to conquer
human genetic diseases and cancers. In terms of experimental practice, the CRISPR-Cas
system is characterized by its simplicity to use, high success rate, and easiness in design,
construction, as well as delivery [156]. Additionally, targeted mutations in multiple genes
(also known as multiplex genome engineering) are possible with the CRISPR-Cas
system. Thus, these features make the innovative CRISPR-Cas system an extremely
valuable tool for the evaluation of investigational gene therapies. Ultimately,
Emmanuelle Charpentier and Jennifer Doudna won the 2020 Nobel Prize in Chemistry
“for the development of a method for genome editing”.

Table 2. Three original developers of the CRISPR-Cas9 system.
P rincipal investigator
Institute

D iscovery

C om pany founder
R eference

Jen n ifer A . D oudna
U niversity o f
C alifornia, B erkeley,
U SA
The use o f C RISPRCas9 system to edit
DNA
C aribou B iosciences,
Inc. and E ditas
M edicine, Inc.
[176]

E m m anuelle
C harpentier

F eng Z hang

U m ea U niversity,
Sw eden

M assachusetts Institute
o f Technology, U SA

The use o f C RISPRCas9 system to edit
DNA

T he application o f
C R ISPR -C as9 in
m am m alian cells

C R ISPR T herapeutics
Co.

E ditas M edicine, Inc.

[176]

[177]
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5.3.2. Mechanism of CRISPR-Cas Action. The CRISPR/Cas system is a
ribonucleoprotein complex and comprises two key components: a chimeric single-guide
RNA (sgRNA) and a DNA endonuclease Cas protein for genome editing [105, 179].
Together, an appropriate sgRNA carries a Cas nuclease to target a specific genomic
sequence. The detailed mechanism of CRISPR-Cas system comprises three phases, which
are adaptation of spacer sequences, expression and mutation, and interference [180]. As
of 2018, CRISPR-Cas systems are classified into three main types of Cas variants (and a
dozen subtypes) have been developed and differ in their mechanisms of action [175,
179].
The first Cas system is the wild-type Cas9 protein from the type II CRISPR
system of Streptococcus pryogenes, and is commonly used as a genome editing tool
[176]. The original activity of this Cas9 protein cleaves DNA at specific sites, resulting in
the creation of double strand breaks (DSBs). DSBs are then subjected to the error-prone
repair by NHEJ or HDR [156]. The efficiency of CRISPR-induced HDR may be very
low in vivo due to HDR being limited to S and G2 phase cells. The second Cas9 variant
is Cas9D10A (a.k.a., nickase) [181], a mutant form of the Cas9 protein which cleaves
only one DNA strand or modifies only one specific nucleotide [175, 179]. This activates
the high-fidelity HDR pathway and downregulates NHEJ-mediated repair. The third Cas9
version is dCas9 (dead Cas9, nuclease-deficient Cas9, or CRISPR interference; i.e.,
CRISPRi) [182], in which certain mutations were introduced to inactivate the protein’s
cleavage activity but retain the DNA-binding activity. This dCas9 is a DNA complexing
protein that can specifically interfere with transcription and modulate gene expression. It
shall be remarked that the number and diversity of CRISPR-Cas systems are continuously
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expanding. Recently, a new evolutionary classification has been introduced to include 2
classes, 6 types, and 33 subtypes [183]. The class 1 systems include multiple Cas proteins
that form a CRISPR RNA-binding complex. By contrast, class 2 systems have a single,
multidomain CRISPR RNA-binding protein, such as Cas9 in type II systems.
Several methods have also been developed related to CRISPR-Cas systems. Prime
editing is a genome editing technique that produced higher precision and a wider
selection of applications, potentially enabling researchers to correct up to 89% of known
genetic variants [184]. This versatile and precise genome editing method uses a
catalytically impaired Cas9 fused to an engineered reverse transcriptase and a prime
editing guide RNA (pegRNA) that both specify the target site and encode the desired
edit. Anti-CRISPRs (Acrs) are small proteins that have been identified to inhibit the
RNA-guided DNA targeting activity of CRISPR-Cas proteins [185]. Three inhibitors,
AcrIIA13, AcrIIA14, and AcrIIA15, were found to block CRISPR-Cas-mediated genome
editing in human embryonic kidney cells. These inhibitors share a conserved N-terminal
sequence that is required in DNA cleavage inhibition. Notably, a new base editor (BE)
was developed by fusing dCas9 and cytidine deaminase that enabled the direct,
irreversible conversion of one target DNA base into another in a programmable manner,
without DSBs [186]. Instead of possible disruption of the entire genome, this BE creates
point mutations at a targeted genomic locus with an efficiency of up to 75% using a
CRISPR framework. This tool is like using an eraser and pencil to fix just a single letter.
Another new CasRx ribonuclease effector was recently identified to exhibit favorable
efficiency and specificity relative to RNA interference (RNAi) across diverse endogenous
transcripts [187]. CasRx can be flexibly packaged into adeno-associated viruses to
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manipulate alternative splicing, reducing pathological tau isoforms in a neuronal model
of frontotemporal dementia.
5.3.3.

Applications of CRISPR-Cas in Gene Therapy. In the post-CRISPR-Cas

era, we have observed incredible increases in laboratory research from academic
institutes and clinical applications from pharmaceutical companies. It was estimated that
the genome editing market will be worth more than US$5 billion by 2021 [188].
Although the driving force of this rapid development was certainly CRISPR-Cas, both
ZFNs and TALENs platforms reached the clinical stage before CRISPR-Cas. Many
teams and companies have been working to translate CRISPR-Cas technologies into safe
and effective human therapeutics [1, 188-192]. For instance, the Genome Project-write
(GP-write) is an open, international research project, which focuses on whole genome
engineering of human cell lines and other organisms of agricultural and public health
significance [193]. In any case, genome editing must be accurate, efficient, and
deliverable to the desired cells or tissues for safe and effective clinical use ex vivo and in
vivo [194]. Currently, there are 10 clinical CRISPR studies under either recruiting or not
yet recruiting status according to ClinicalTrials.gov [195]. In 2020, there were 19
ongoing clinical trials using CRISPR-based gene editing [196]. However, none of these
proposed clinical trials has been officially approved as new drugs by the US FDA. [190].
Since the discovery of the CRISPR-Cas system in 2012, the progress toward
human trials has been slow [197]. For example, US FDA halted the proposed trial of
CTX001 to use the CRISPR-Cas system for a single genetic change in patients with
sickle cell disease. The status of the European trial using the same treatment in patients
with beta-thalassemia was unaffected by this US FDA decision, and was still planned to
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be initiated later in 2018. In 2015, it was reported that the first CRISPR-Cas human
clinical trial took place in China [190, 198]. There were 86 patients with various cancers
that participated in these clinical CRISPR-Cas trials from 2015 to 2017. At least 15
patients died during the trials, although the directors of clinical research claimed they
died from their own cancers. One of the clinical trial directors from Hangzhou Cancer
Hospital revealed that the cure rate of an ex vivo clinical CRISPR-Cas trial after 11
months was approximately 40% from 21 patients with esophageal cancer [199].
However, no official or complete results from Chinese CRISPR-Cas human clinical trials
have been reported to date. In November 2018, a Chinese biophysics researcher, He
Jiankui, sent shockwaves across the world by claiming that he had utilized CRISPR
technology to edit the genomes of two twin babies, Lulu and Nana [200]. His team
attempted to introduce a mutation into their CCR5 genes, a gene encoding the T cell
receptor that HIV viruses bind to, in order to prevent HIV infection. However, the
ethically controversial announcement lead to his dismissal from the Southern University
of Science and Technology in Shenzhen, China. He was also fined three million yuan and
imprisoned for three years by the Chinese People’s Court in 2019.
The ongoing global pandemic of coronavirus disease 2019 (COVID-19), caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most
devastating viral outbreaks in the past 100 years [201]. A rapid (less than 40 minute),
easy-to-implement, and accurate CRISPR-Cas12-based diagnostic assay was developed
for detecting SARS-CoV-2 from RNA extracts of respiratory swabs [202]. This DNA
endonuclease-targeted CRISPR trans reporter (DETECTR) assay provides a visual and
faster alternative to general assays. Additionally, a CRISPR-Cas13-based antiviral
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strategy was recently developed to target conserved sequences of coronaviruses and
influenza A virus [203]. This strategy was named prophylactic antiviral CRISPR in
human cells (PAC-MAN) and effectively degrades RNA from SARS-CoV-2 and
influenza A virus in human lung epithelial cells. Bioinformatic analysis showed that a
group of only six CRISPR RNAs can target more than 90% of all coronaviruses.
5.3.4. Concerns of CRISPR-Cas in Gene Therapy. Serious safety concerns
about the use of CRISPR-Cas have been raised after the development of therapeutic
genome editing applications [204]. CRISPR-Cas technology has enabled efficient
genome editing and modifications in several model organisms, and has successfully been
applied in biomedicine and biomedical engineering [205]. Much attention has also
focused on the development of potential CRISPR-Cas therapies to cure complex heritable
diseases in humans [206]. However, major challenges related to the effectiveness,
specificity, and safety of the CRISPR-Cas system remain. Notably, safety guidelines for
preclinical trial studies and ethical issues concerning genome editing and genomic
analysis at the population level remain unsettled.

6. CONCLUSIONS

Gene therapy has evolved and improved over the past five decades. Methods
started from non-specific and non-targeting and have become specific and precise with
the ability to target genes that need to be corrected to eliminate disease. Correction can be
an addition or a simple edit to a small stretch of a gene. Genetic delivery has been
achieved at the cellular level and organismal level. CRISPR systems have gathered the
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main attention of gene therapy research due the system being viewed as an accurate and
efficient technique with the potential to challenge all diseases. Gene delivery and genome
editing will continue to develop in the twenty-first century, with advances in delivery
efficiency and targeting specificity, though progress may be gradual due to necessary
safety precautions. We have learned from past mistakes, where safety was not fully
considered, and have faced morbidity and mortality among patients. Certain methods are
likely to become more effective and safer for disease management, but other methods
will still remain competitive due to ease of preparation and use, low cost, simplicity, and
will still contribution to fundamental scientific endeavors in cell and molecular biology.
As these techniques continue to develop, more applications will arise, treatments will be
further tailored to individuals, and diseases with more complex genotypes will be able to
be treated. As genome therapy becomes safer and highly efficient, we will be faced with
more cases of edited humans and must question the line between disease treatment and
playing god with our genetic code.
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ABSTRACT

Breast cancer affects the lives of millions of women around the world each year.
Triple negative breast cancers (TNBCs) lack therapy methods with few side-effects. Less
harsh treatment options are necessary to improve the overall outcome for cancer patients.
DNA origami is a promising nanocarrier system. However, the uptake mechanism of this
carrier is not well understood. In this study, we describe the killing efficiency of a model
DOX-loaded DNA triangle origami (DOX-DNA-T) using viability reduction and
apoptosis induction in two TNBC cell lines (MDA-MB-231 and MDA-MB-453). The
internalization pathway of DOX-DNA-T was elucidated by inhibiting energy-dependent,
clathrin-dependent, caveolin-dependent, and macropinocytosis pathways. The subcellular
localization of DOX-DNA-T was determined by co-localization with organelle-specific
dyes using a confocal microscope. DOX-DNA-T was able to increase the internalized
DOX concentration and altered its subcellular localization. DOX-DNA-T delayed the
killing of DOX, but modulated the toxicity between cell lines. The carrier facilitated
DOX entry by clathrin- and caveolin-dependent endocytosis, as well as by
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macropinocytosis. Understanding the cellular fate of DOX-DNA-T can help to better
design DNA nanostructures as a drug delivery system.

1. INTRODUCTION

In 2018, 18.1 million new cases of cancer were diagnosed worldwide [1]. Breast
cancer contributed 11.6% of these cases and remains the second leading cause of all
cancer related deaths, despite years of research and funding in the field [1]. Breast
cancers are classified based on receptor upregulation and overexpression compared to
normal tissue. The three most commonly upregulated and targeted receptors for treatment
are the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal
growth factor receptor (HER-2) [2]. However, these three receptors are absent in 15 to
20% of breast cancers, which are referred to as triple negative breast cancer (TNBC) [2].
Consequently, approximately 367 thousand new cases of TNBC are diagnosed yearly,
based on global cancer statistics. Because TNBCs lack the three common breast cancer
receptors, they do not respond well to frequently used targeted therapies [2]. Recurrence
and metastasis are also significantly higher in patients with TNBCs [3]. Metastasis is a
large concern when treating cancer patients as metastasis is the cause of 90% of all
cancer deaths [4]. Aggressiveness (i.e., fast formation and growth) and invasiveness
make triple negative tumors difficult to remove surgically without causing harm to the
surrounding healthy tissue [5]. All these factors result in worse prognosis for patients
with TNBC compared to other breast cancers.
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There are few treatment options for patients with TNBCs and no FDA-approved
targeted therapies against the cells of TNBC tumors [2]. Conventionally, TNBCs are
treated by surgically removing the tumor mass in combination with radiation or
chemotherapy [5-7]. During the course of treatment, a cancer patient is likely to receive
anthracyclines (e.g., Doxorubicin, DOX), which efficiently kill cells that are actively
replicating [8-10]. However, anthracyclines also destroy non-cancerous cells that quickly
replicate. Even if they are not replicating, cells may be harmed as the metabolic reduction
of anthracyclines results in hydroxyl free radicals [11]. Cardiomyocytes are particularly
susceptible to damage by the free radicals produced by anthracyclines, resulting in side
effects as severe as congestive heart failure [11]. Furthermore, resistance to DOX often
develops in cancerous tissues treated with the drug [11], presenting major challenges for
cancers with few treatment options or for recurring cancers. In order to decrease side
effects of anticancer drugs like DOX, various carriers at the nanoscale are in development
which increase drug delivery efficiency using the principle of enhanced permeability and
retention. This principle is observed in tumors where vasculature is abnormally
permeable and lymphatic drainage is low, leading to a buildup of compounds within the
tumor [12]. Delivering drugs directly to tumors using nanocarriers can combat drug
resistance by increasing retention time and can reduce overall toxicity in patients [13-15].
One promising nanoparticle being used for delivery is DNA. Using base pairing, a
long single-strand of circular viral genome can be artificially folded into theoretically any
desired shape with the help of short synthetic DNA strands (staple strands) to act as a
carrier [13]. The resulting nanostructures, or DNA origami, have size-dependent drug
loading capacity and drug release [15]. The amount of drug loaded is tunable based on
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the length of the DNA strands and on DNA helix rotation [16, 17]. The use of DNA in
nanostructures allows precise geometry to be designed and easy functionalization [13,
18]. Exact control of nanostructure geometry is desirable as it influences biodistribution,
movement through fluids, and cellular internalization [19]. Because DNA nanostructures
have been observed to possess a high affinity for and enhanced retention within tumor
masses in vivo [18, 20], they have been evaluated to deliver anti-cancer drugs.
DNA nanostructures are an excellent carrier for anthracyclines, as the drugs
readily intercalate into the DNA double helix and slowly dissociate [14, 15, 21]. In a
previous in vitro study by Zeng et al., drug-loaded DNA nanostructures had higher
accumulation and persistence in cancer cells compared to free DOX [15]. DNA
nanostructures have shown the ability to passively target and localize in tumors in vivo
[18, 20]. Despite the potential success of DNA nanostructure to deliver anti-cancer drugs
to tumors, their exact cellular uptake mechanism and subcellular localization are still
unknown, which are influential to drug delivery efficacy. In this study, we evaluated a
model DOX-loaded DNA triangle origami (DOX-DNA-T) in two different TNBC cell
lines: MDA-MB-231 and MDA-MB-453. We hypothesized that 1) DOX-DNA-T
nanostructures would have more effective cellular uptake and killing efficiency in triple
negative breast cancer cells than DOX alone, 2) the uptake mechanism of DOX-DNA-T
would be energy dependent, and 3) DOX-DNA-T would localize within cellular
organelles. This study provides insight to the cellular uptake mechanisms and the
subcellular fate of DNA origami, with the potential to further improve the therapeutic
efficacy of DNA origami as a carrier system.
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2. MATERIALS AND METHODS

2.1. DNA ORIGAMI PRODUCTION
Triangle origami were prepared from synthetic L-form M13mp18 phage single
stranded genomes (Bayou Biolabs: Metairie, LA, USA) using techniques described in our
previous publications [15]. Briefly, genomes and appropriately designed staple strands
(Integrated DNA Technologies: Coralville, IA, USA) were mixed, incubated at 90°C, and
allowed to anneal over a slow 12-hour cool down to room temperature. Desired shape
was confirmed with atomic force microscopy (AFM). DOX (Fisher BioReagents:
Pittsburgh, PA, USA) was loaded into the origami by incubating the folded structures
with 1.2 mM of the drug for 18 hours at 37°C. Loading efficiency was calculated based
on the concentration of free DOX in solution after pelleting the loaded origami and was
in the range of 85 to 95%. The concentration was determined using a fluorescence
spectrophotometer set to excite at 485 nm and record at 500 to 650 nm (Nanodrop 3300,
ThermoFisher Scientific: Waltham, MA, USA), with the final concertation loaded being
approximately 1 mM per 5 nM of origami. The stability of complexes was confirmed by
incubation with different concentrations (2, 5, and 10%) of HyClone fetal clone serum
(FCS, GE Healthcare Life Sciences: Marlborough, MA, USA), which is rich in proteases
and DNases normally found in the blood. After incubation for various time periods,
origami was run on 0.8% agarose gels containing ethidium bromide and imaged. Unless
otherwise noted, the range of concentrations used to treat cells were 0, 0.0025, 0.005,
0.01, 0.025, and 0.05 nM of naked origami; 0, 0.5, 1, 2, 5, and 10 pM of free DOX; or the
equivalent concentrations of each component combined in DOX-DNA-T.
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2.2. CELL MAINTENANCE
MDA-MB-231 and MDA-MB-453 cell lines were purchased from the American
Type Culture Collection (ATCC: Manassas, VA, USA) and were cultured in RPMI-1640
medium supplemented with 5% HyClone FCS and 1% antibiotics (50 units/mL penicillin
and 50 pg/mL streptomycin). Cells were maintained in tissue culture dishes in a
humidified incubator at 37°C and 5% CO2. Both cell lines were harvested upon reaching
80 to 90% confluency using trypsin for experiments or were split 1:2 to 1:4 every 2 to 4
days. Cultures were replaced with cells from liquid nitrogen storage before exceeding 30
passages. The pH of cultures was analyzed 24 and 48 hours after cells were established
for 24 hours in order to determine if there were additional differences between the
physiological conditions of the cells.

2.3. CELL VIABILITY
The viability of MDA-MB-231 and MDA-MB-453 cells was determined by
seeding 50,000 cells for 48-hour and 100,000 cells for 24-hour experiments into 24-well
cell culture plates with equal cell density per well. A lower starting density was used for
longer incubations to prevent overcrowding in controls. Cells were allowed to adhere to
the plates for 24 hours and then dosed with a concentration range of each component of
the triangle origami. Viability was compared between naked origami, free DOX, and
DOX-DNA-T. Viability was accessed using a standard sulforhodamine B (SRB) protein
dye assay [22]. Briefly, after exposure for 24 or 48 hours, cells were fixed in 500 pL of
10% trichloroacetic acid for 1 hour at 4°C. Cells were rinsed with distilled water three
times, excess water was removed by pipet, and plates were allowed to dry completely in a
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refrigerator (at least overnight). Following drying, cells were stained with 500 gL of
0.2% SRB in 1% acetic acid for 30 minutes on a rocker. Cells were then washed three
times with 1% acetic acid, with each wash sitting for 20 minutes on the rocker. Excess
acetic acid was removed from the wells and plates were air dried for 30 minutes. TrisHCl (300 gL, 10 mM) was used to dissociate the dye from cellular proteins, 250 gL of
the dye solution was transferred to a 96-well microplate, and color intensity was
measured using a FLUOstar Omega microplate reader set to read absorbance at 510 nm
(BMG Labtechnologies: Cary, NC, USA). Wells with no cultured cells that were stained
and washed served as blanks. Cell viability was calculated as the sample well intensity as
a percentage of the control well intensity, with blanks subtracted from both.
Cell viability, or culture growth, was also analyzed for MDA-MB-231 cells after
incubation in media with different concentrations of FCS (2, 5, and 10%) to establish the
appropriate testing conditions for the DNA origami. Cells were seeded at 80,000 cells per
well in 24-well cell culture plates. Cells were grown until attached, approximately 4.5
hours, and fixed to serve as a 0-time point. Other cells were grown for 24, 48, and 72
hours after the 0-time point, fixed, and analyzed using the SRB assay. Cell viability was
calculated as the sample well intensity as a percentage of the highest well intensity, with
appropriate blanks subtracted from both.

2.4. APOPTOSIS
Annexin V-Alexa Fluor 647 is a dye that binds with high affinity to
phosphatidylserine, a cell signaling molecule expressed on the cell surface during
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apoptosis [23]. Quantification of this molecule allows the portion of cells undergoing
apoptosis to be determined.
For flow cytometry, MDA-MB-231 or MDA-MB-453 cells (300,000 cells per
dish for 48-hour and 600,000 cells per dishfor 24-hour) were grown in 6 cm cell culture
dishes for 24 hours before dosing with a concentration range of DOX or DOX-DNA-T
for either 24 or 48 hours. After exposure, cells were washed with phosphate buffered
saline (PBS), suspended from the plates using trypsin, and pelleted by centrifugation. The
old media and PBS wash were collected and pelleted along with the trypsinized cells in
order to prevent the loss of floating cells undergoing apoptosis. Cells were suspended in
1 pL of Annexin V-Alexa Fluor 647 (50 pg/mL, BioLegend: San Diego, CA, USA) in
100 pL of 1x Annexin V-binding buffer (BD Biosciences: San Jose, CA, USA), with a
final dye concentration of 0.5 pg/mL. Cells were incubated with Annexin V-Alexa Fluor
647 for 30 minutes at room temperature in the dark before analysis using a CytoFLEX
flow cytometer (Beckman-Coulter: Brea, CA, USA) with the far-red filter set (ex: 638
nm, em: 660/10 nm). For each experiment, 10,000 to 30,000 single cell events were
captured. The population of cells undergoing apoptosis was determined using FCS
Express 6 analysis software. Cells were considered apoptotic if they were positive for
Annexin V staining.
For confocal microscopy, MDA-MB-231 or MDA-MB-453 cells (150,000 cells
per dish for 48-hour and 300,000 cells per dish for 24-hour) were grown in 3.5 cm glassbottomed cell culture dishes (MatTek: Ashland, MA, USA) for 24 hours before dosing
with 10 pM of free DOX or an equivalent amount of DOX loaded into DNA-T. After
exposure for 24 or 48 hours, old media was collected and cells were washed twice with
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PBS. The first wash and old media were collected and centrifuged to harvest floating
cells. The second wash was left on cells while centrifuging the media to prevent drying
and was then discarded. Pelleted cells were suspended in 5 pL of Annexin V-Alexa Fluor
647 (BioLegend, 50 pg/mL) in 500 pL of Annexin V-binding buffer, with a final dye
concentration of 0.5 pg/mL. Dye solution and floating cells were then pipetted back into
the sample dishes and evenly distributed by tilting the dish. Dishes were incubated for 30
minutes at 37°C in the dark. Following incubation with Annexin V, cells were incubated
with 1 mL of Hoechst 33342 (10 mg/mL stock, diluted 1:2000 in PBS) for 5 minutes at
37°C in the dark. Cells were then imaged using a Nikon A1R HD25 confocal microscope
comparisonusing a 40x Plan Fluor objective with 1.3 NA (Nikon Instruments: Melville,
NY, USA). Green (ex: 488 nm, em: 500-550 nm), far-red (ex: 640 nm, em: 663-673 nm)
and blue (ex: 405, em: 425-475 nm) filter sets were used to detect DOX, Annexin V, and
Hoechst, respectively. Images were obtained using Elements software and a four channel
High-Sensitivity/GaAsP PMT detector unit. Confocal images were analyzed in ImageJ
(National Institutes of Health).

2.5. UPTAKE
Unless otherwise noted, the following setup was used for uptake experiments.
MDA-MB-231 and MBA-MB-453 cells used for flow cytometry analysis were seeded
into the wells of a 24-well plate at a density of 100,000 cells per well and allowed to
grow for 48 hours before treatment. Drug concentration was selected to be 2 pM in
uptake studies to limit cell death and ensure cells were healthy enough for internalization.
DOX intensity was measured on a flow cytometer using the green filter set (ex: 488 nm,
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em: 525/40 nm), as DOX itself is fluorescent with a peak excitation wavelength of 470
nm and emission of 560 nm [24]. For each experiment, 10,000 to 30,000 single cell
events were captured. For confocal microscopy, MDA-MB-231 and MBA-MB-453 cells
were plated in 3.5 cm glass-bottom culture dishes at a density of 300,000 cells per dish
and allowed to adhere for 48 hours. DOX intensity was also analyzed using a 488 nm
laser line on the confocal. Confocal images were analyzed in ImageJ. All cells were
washed twice before harvesting with trypsin or imaging. Pelleted cells were suspended in
150 pL of PBS for flow cytometry. Cells were imaged in 1 mL of warm PBS. All
inhibitor solutions were sterilized by using 0.2 pm syringe filters. Concentrations for
inhibitors were the same as the ones used for our previous publication [25]. Live cell
fluorescence was examined within 1 hour of washing or harvesting. Confocal images
were analyzed in ImageJ.
2.5.1. Subcellular Localization. DOX-DNA-T were expected to be subcellularly
localized in the lysosome, mitochondria, or nuclei. Using LysoTracker (Deep Red,
Invitrogen: Carlsbad, CA, USA), MitoTracker (Deep Red, Invitrogen), and Hoechst
33342, subcellular localization was revealed by co-localization with these specific
markers. MDA-MB-231 and MBA-MB-453 cells were plated in 3.5 cm glass-bottom
culture dishes and grown for 24 hours for microscopy. Cells were treated with 2 pM of
DOX or DOX-DNA-T for 24 or 48 hours. The treated or untreated cells were incubated
with specific markers following the instructions provided by the manufacturers. Briefly,
LysoTracker and MitoTracker were prepared as 100x stock solutions and diluted in fresh
media to 50 nM. Media was prewarmed and 2 mL of each solution was added to cells.
Cells were incubated for 30 minutes at 37°C in the dark. Staining solution was discarded
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and samples were then incubated with 1 mL of warm Hoechst 33342 (10 mg/mL stock,
diluted 1:2000 in PBS) for 5 minutes at 37°C in the dark. The cells were washed twice
with warm PBS, 1 mL of warm PBS was added to each dish to keep the cells moist, and
cells were then imaged using a confocal microscope.
2.5.2. Time-Dependent Uptake. The internalization of DOX and DOX-DNA-T
was determined over the course of 0 to 4 hours and after 24 and 48 hours using flow
cytometry. Cells were plated in 6-well culture plates at a density of 500,000 per well and
allowed to grow for 48 hours before dosing with 2 pM of DOX or DOX-DNA-T. During
0- to 4-hour experiments, cells were dosed at 0 minutes, 10 minutes, 30 minutes, 1 hour,
2 hours, and 4 hours before washing. For 24- and 48-hour experiments, cells were plated
at 225,000 cells per well and 112,500 cells per well in 3.5 cm culture dishes, respectively,
and allowed to grow for 48 hours before dosing. Surface area was accounted for in order
to achieve the same cell density in different culture vessels. Select time points (1, 24, and
48 hours) were chosen be imaged using a confocal microscope for visual comparison.
2.5.3. Energy Inhibition. Multiple forms of endocytosis, including clathrin- and
caveolin-dependent endocytosis, as well as macropinocytosis, require energy for vesicle
formation at the cell surface [26]. MDA-MB-231 and MBA-MB-453 cells were plated
into a 24-well plate or glass-bottomed culture dishes for flow cytometry or microscopy,
respectively. An inhibitor cocktail was prepared at 100x in water and diluted to 10x in
PBS. Cells were pre-incubated with the metabolic inhibitor mixture (230 pM of sodium
azide, 15 pM of sodium fluoride, and 2 pg/mL antimycin A) for 1 hour, followed by
incubation with 2 pM of DOX or DOX-DNA-T for 1 hour. Cells were then imagined
with a Nikon confocal microscope or harvested for analysis using a flow cytometer. DOX
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was expected to diffuse into cells [27-30], so further inhibition studies were carried out
using only DOX-DNA-T.
2.5.4. Clathrin Inhibition. MDA-MB-231 and MBA-MB-453 cells were plated
into a 24-well plate or glass-bottomed culture dishes for flow cytometry or microscopy,
respectively. A 2x working solution of sucrose was prepared in water. A 1000x stock
solution of chlorpromazine was prepared in water and was diluted to a 10x working
solution in PBS. A 100x stock solution of monodansylcadaverine (MDC) was prepared in
100% methanol and was diluted to a 10x working solution in PBS. Cells were pre
incubated with 0.45 M sucrose, 10 pM chlorpromazine, or 25 pg/mL MDC for 30
minutes at 37°C. Cells were treated with 2 pM of DOX-DNA-T for 1 hour and then
imagined with a Nikon confocal microscope or harvested for analysis using a flow
cytometer.
2.5.5. Caveolae Inhibition. To inhibit lipid raft-dependent caveolin endocytosis,
filipin and nystatin were used to sequester cholesterol [31]. MDA-MB-231 and MBAMB-453 cells were plated into a 24-well plate or glass-bottomed culture dishes for flow
cytometry or microscopy, respectively. A 100x stock solution of filipin was prepare in
1:4 DMSO:PBS and was diluted to a 10x working solution in PBS. A 100x stock solution
of nystatin was prepare in 100% methanol and was diluted to a 10x working solution in
PBS. Cells were pre-incubated with 3 pg/mL filipin or 20 pg/mL nystatin for 30 minutes
before treatment with 2 pM of DOX-DNA-T for another 1 hour. Cell were then imagined
with a Nikon confocal microscope or harvested for analysis using a flow cytometer.
2.5.6. Macropinocytosis Inhibition. MDA-MB-231 and MBA-MB-453 cells
were plated into a 24-well plate or glass-bottomed culture dishes for flow cytometry or
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microscopy, respectively. Cells were pre-treated with EIPA (5-(N-ethyl-N-isopropyl)amiloride (30 pM) or cytochalasin D (Cyt D, 1 pg/mL) for 30 minutes before treatment
with 2 pM of DOX-DNA-T for another 1 hour. EIPA was prepared as 2 mg/mL stock
solution in 100% methanol and diluted to 10x in PBS. Cyt D was prepared as 1 mg/mL
stock solution in 100% ethanol and diluted to 10x in PBS. Cells were then imagined with
a Nikon confocal microscope or harvested for analysis using a flow cytometer.

2.6. STATISTICAL ANALYSIS
Data are expressed as the mean ± standard deviation. One-way ANOVA followed
by Tukey tests were used to compare the differences between all groups. A student’s ttest was used to compare differences between specific treatment groups and controls. All
statistics were performed in MiniTab 19 and most graphs were produced in GraphPad
Prism 4. Each in vitro experiment was carried out in at least three independent
experiments. Statistical significance was set at p < 0.05.

3. RESULTS

3.1. DNA ORIGAMI PRODUCTION
DNA origami triangle folding and shape were confirmed using AFM (Figure 1A).
DNA-T were approximately 50 nm across and their geometry was not altered by the
intercalation of DOX. DNA-T showed higher stability in lower concentrations of FCS
(Figure 1B), with the least band streaking observed in 2% FCS and the highest observed
in 10% FCS. In 10% FCS, origami bands showed low streaking after initial mixing, but
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were destabilized relatively quickly. In 5% FCS, origami bands showed similar streaking
from 0 to 8 hours, but began to show increased streaking after 12 and 24 hours. In 2%,
origami appear to be stable after 16 hours of incubation.
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Figure 1. DNA structure and stability confirmation using AFM and agarose gels. (A)
AFM images of DNA origami triangles. Scale bar is 100 nm. (B) Agarose gel showing
the stability of DNA-T incubated in RPMI-1640 cell culture medium (Left 10%, middle
5%, and right 2% FCS) for the indicated time period.

3.2. CELL VIABILITY
Ideally, DNA-T would be tested in low concentrations of FCS to retain high
stability. However, it was unknown if breast cancer cells would retain substantial culture
growth if incubated with 2% FCS. The growth of MDA-MB-231 cells in media with
different concentrations of FCS was tested using a SRB assay in order to determine the
best concentration to use for DNA-T testing (Figure 2). MDA-MB-231 culture growth
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was significantly different at all concentrations of FCS (N = 7, p’s < 0.05). However,
incubation with 5 and 10% FCS resulted in similar increasing growth at all time points.
Cells did not grow nearly as well in 2% FCS and the population did not increase from 48
to 72 hours. Therefore, 5% FCS was chosen to provide stability to DNA-T and allow the
breast cancer cell cultures to retain a normal amount of growth.

FCS Viability
□

10%

^

2%

Time (hours)

Figure 2. MDA-MB-231 population in 10, 5, and 2% FCS. The cell population after 72h
in 10% FCS was the maximum and was normalized to 100%. This population was used
to normalize all other treatment groups, * indicates significance vs. 0-time point and A
indicates significance vs. 10% FCS at a given time point (p’s < 0.05, ANOVA with
Tukey’s post hoc test). The populations between 2% FCS at 48 and 72 h FCS were not
different. N = 7 per experiment, 1 experiment.

The viability of both cells lines was accessed after treatment with DNA-T, DOX,
and DOX loaded into DNA-T using SRB assays (Figure 3). DNA-T alone did not affect
the survival of MDA-MB-231 or MDA-MB-453 cells, which was expected (N = 9, p’s >
0.5). The viability of both cell types in DOX and DOX-DNA-T was time- and
concentration-dependent. Higher concentrations and longer times resulted in more death.
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DOX alone killed more cells after 24 hours than DOX-DNA-T, with significant decreases
at 2 through 10 gM in MDA-MB-231 and at 1 through 10 gM in MDA-MB-453 (N = 9,
p’s < 0.005). Cell viability dropped to 46 and 45% in MDA-MB-231 and MDA-MB-453
cells after 10 gM of DOX exposure for 24 hours, respectively. DOX-DNA-T only
showed a significant decrease at 5 and 10 gM of DOX in MDA-MB-231 and only at 10
gM in MDA-MB-453 (N = 9, p’s < 0.05) with 24-hour exposure. The resulting viabilities
were 76 and 78% in MDA-MB-231 and MDA-MB-453, respectively, after 24-hour
incubation with 10 gM of DOX-DNA-T. After 48 hours of exposure, DOX also
decreased viability at lower concentrations, which both cell lines experiencing significant
decreases at 0.5 through 10 gM (N = 9, p’s < 0.005). DOX-DNA-T treatment for 48
hours showed a significant decrease in viability at 2 through 10 gM in both cell lines and
additionally at 1 gM for MDA-MB-231 (N = 9, p’s < 0.005). Both treatments reduced the
viability of the cell lines down to a similar level after 48-hour 10 gM exposure, with
survival being approximately 7 to 11%.

Table 1. Acidity of MDA-MB-231 and MDA-MB-453 cultures. Mean pH ± the SD.
Time
24h
48h

____________________ PH____________________
231
453
Media
7.12 ± 0.03
7.47 ± 0.03
7.47 ± 0.02
7.04 ± 0.03
7.42 ± 0.02

MDA-MB-453 seemed more susceptible to DOX alone than MDA-MB-231, with
lower viability at 1 through 5 gM after 24 hours and at 0.5 through 2 gM after 48 hours.
Loading DOX into DNA seemed to modulate the differences in viability between the two
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cell lines. Differences in toxicity were not likely due to altered pH between the cell types,
as cell culture media remained around neutral pH (Table 1).
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Figure 3. Viability of MDA-MB-231 and 453 cells after exposure to (A) DNA-T alone,
(B) free DOX, and (C) DOX-DNA-T for 24 and 48h. Untreated cell population was
considered 100% viable and used to normalize the viability of other groups. Treated cell
population was calculated as a percentage of the control and compared to the control and
other groups using one-way ANOVA with Tukey’s post hoc test, * p’s < 0.05. N = 3 per
experiment, 3 experiments.

3.3. APOPTOSIS
DOX exposure produced a much higher rate of total apoptosis compared to DOXDNA-T overall (Figure 4). After 48 hours, 10 pM of DOX resulted in 20% and 51% of
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MDA-MB-231 and MDA-MB-453 cells undergoing apoptosis, respectively, while 10 ^M
of DOX-DNA-T after 48 hours resulted in 20% and 16% in the same cell lines. For DOX
alone, apoptosis at both time points and in both cell lines was significantly increased at 5
and 10 ^M (N = 3, p’s < 0.05). At 2 ^M of DOX, 24- and 48-hour MDA-MB-453, as
well as 48-hour MDA-MB-231 were significantly higher (N = 3, p’s < 0.01). MDA-MB231 also showed significance at 1 ^M of DOX after 48-hour exposure (N = 3, p’s < 0.05).
DOX-DNA-T did not induce significant apoptosis at any concentration after 24 hours,
except for 2 ^M in MDA-MB-453 cells, which was not substantially higher than the
control. After 48 hours, MDA-MB-453 showed significantly higher apoptosis at 1
through 10 ^M and MDA-MB-231 at 5 and 10 p,M of DOX-DNA-T (N = 3, p’s < 0.05).
Example flow cytometry data is shown in Figure 4C and D.
Figure 5 shows confocal images of MDA-MB-231 and MDA-MB-453 cells after
24- and 48-hour exposure to 10 ^M of DOX and DOX-DNA-T. Results were visually
comparable to flow data, with cells exposed to DOX alone appearing to have more
visible red apoptosis staining than DOX-DNA-T treated cells. Cells treated with DOXDNA-T also appeared to have a higher concentration of DOX within them, based on the
greater fluorescence intensity observed. DOX seemed to be localized in the cytoplasm in
both cases. Morphological analysis of the cells with DIC imaging (Figure 6) revealed
more debris in cultures treated with DOX-DNA-T and more blebbing cells in cultures
treated with DOX alone. Debris in DOX-DNA-T treated cultures were dark and did not
appear to have much staining. Some cells appeared to have this debris associated with the
cell surface.

83
(A)
DOX Apoptosis

(B)
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Figure 4. Total apoptosis of MDA-MB-231 and MDA-MB-453 cell lines after exposure
to (A) DOX and (B) DOX-DNA-T for 24 and 48h, quantified using flow cytometry. The
percentage of cells positive for Annexin V staining were considered apoptotic. Example
flow cytometry data of (C) 453 cells with no drug exposure and (D) 453 cells after 48h
DOX exposure. Samples were compared to the control and other groups using one-way
ANOVA with Tukey’s post hoc test, * p’s < 0.05. N = 3 experiments, with 10-30k cells
per sample.
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DOX-DNA-T (10 uM)

24h
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24h
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Figure 5. Confocal images of cells undergoing apoptosis after exposure to 10 gM of
DOX or DOX-DNA-T. Blue is Hoechst, red is Annexin V, and green is DOX. White
arrowheads indicate blebbing cells and white-outlined black arrowheads point to
apoptotic bodies. Scale bar is 50 gm, 40x oil objective.
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Figure 6. Morphology of cells after exposure to 10 pM of DOX and DOX-DNA-T. White
arrowheads point to debris in solution and white-outlined black arrowheads point to
membrane-associated debris. Scale bar is 50 pm, 40x oil objective.
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Figure 7. Localization of (A) DOX and (B) DOX-DNA-T in MDA-MB-231 (left) and
MDA-MB-453 (right) after 24h. Blue is Hoechst, green is DOX, and red is LysoTracker.
Cells were treated with 2 gM of either free DOX or DOX-DNA-T for 24h. Scale bar is 10
gm in XY, XZ, and YZ. Images are 5x zoomed in areas from a 60x oil objective field. Zstacks were imaged 25 gm around the focal point, with a 1 gm step. Full field images can
be found in the supplementary data.
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3.4. UPTAKE
3.4.1. Subcellular Localization. DOX alone localized into the lysosome based
on green DOX fluorescence co-localizing with the red LysoTracker in both cell lines
(Figure 7). DOX-DNA-T were expected to be subcellularly localized in the lysosome,
mitochondria, or nuclei. However, DOX-DNA-T was dispersed through the cell
cytoplasm, had low nuclear localization, and had relatively low lysosomal localization
compared to DOX alone. MDA-MB-453 seemed to have lower DOX-DNA-T lysosomal
localization compared to MDA-MB-231, which seemed to increase from 24 to 48 hours.
MDA-MB-453 had noticeably smaller lysosomes compared to MDA-MB-231.
Localization did not seem to differ substantially between 24 and 48 hours and neither free
DOX nor DOX-DNA-T seemed to localize within the mitochondria (Appendix Figures 1
8).
3.4.2. Time-Dependent Uptake. The internalization of DOX and DOX-DNA-T
was determined over the course of 0 to 4 hours and after 24 and 48 hours using flow
cytometry (Figure 8). Select time points (1, 24, and 48 hours) were chosen be imaged
using a confocal microscope for visual comparison. In both cell lines, DOX uptake was
significant from 1 to 4 hours and after 24 and 48 hours (N = 3, p’s < 0.005). DOX uptake
was significantly different between 24- and 48-hour incubation (N = 3, p’s < 0.05). DOX
uptake after 24 and 48 hours was not different between the two cell lines (N = 3, p’s >
0.05). Internalization during 30 minutes to 4 hours and after 24 and 48 hours was
significant after DOX-DNA-T exposure (N = 3, p’s < 0.05). DOX-DNA-T uptake was
the same in MDA-MB-453 cells between 24 and 48 hours (N = 3, p’s > 0.5). Although
the average fluorescence of MDA-MB-231 cells was higher after 48-hour DOX-DNA-T
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treatment compared to 24-hour treatment, the two time points were not significantly
different (N = 3, p’s > 0.1). MDA-MB-231 cells did show significantly higher
fluorescence after incubation with DOX-DNA-T compared to free DOX at both time
points and to DOX-DNA-T treated MDA-MB-453 cells after 48 hours (N = 3, p’s <
0.05). After 24- and 48-hour incubation, MDA-MB-453 cells had similar DOX-DNA-T
fluorescence compared to 48-hour DOX (N = 3, p’s > 0.5). During shorter periods of
time, internalization was similar between the free drug and loaded drug in both cell lines
(N = 3, p’s > 0.1 time point vs. time point), though DNA-T averages were lower at every
time point. MDA-MB-453 internalized more DOX when it was loaded into DNA-T
compared to MDA-MB-231 during the shorter duration incubation, after 2 and 4 hours (N
= 3, p’s < 0.05). Confocal images confirmed that DOX-DNA-T uptake at 1 hour was
similar to DOX alone and was higher than free DOX after 24 and 48 hours (Figure 9).
DOX-DNA-T had a similar diffused appearance after 1, 24, and 48 hours at 2 pM.
However, DOX appeared to be diffused throughout cells after 1 hour and collect into
lysosomes after 24 and 48 hours in MDA-MB-231 and after 48 hours in MDA-MB-453.
3.4.3.

Energy Inhibition. Inhibition studies were carried out with 1-hour drug

incubations as uptake in the first 4 hours did not plateau and 1 hour was the first time
point where all conditions were significantly different from the control. Cells incubated
with metabolic inhibitors and DOX or DOX-DNA-T are shown in Figure 10. The mixture
of metabolic inhibitors prevented energy-dependent internalization by depleting cellular
ATP levels. Sodium azide and antimycin A interfere with the mitochondrial electron
transport chain [32, 33], while sodium fluoride inhibits glycolysis [34]. Cells were
imagined with a confocal microscope or harvested for quantitative analysis using a flow
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Figure 8. Time-dependent uptake of 2 pM of (A) DOX or (B) DOX-DNA-T. The small
graph insert is a magnified 0 to 4h time scale. Significance vs. control is indicated with a
colored *, color corresponding to the line color, p’s < 0.05. A Aindicates significance
between cell lines at a given time point, p’s < 0.05. Analyzed in CytExpert with 525/40
nm filter set (505-545 nm range). Significance between groups and vs. the controls were
determined using one-way ANOVA with Tukey’s post hoc test. N = 3 experiments, with
10-30k cells per sample.
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Figure 9. Time-dependent uptake microscopy of DOX or DOX-DNA-T after 1, 24, and
48h. Drug concentration was 2 pM. Scale bar is 50 pm, 40x oil objective.
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cytometer. DOX fluorescence inside either cell line did not significantly differ after cells
were pre-incubated with a metabolic inhibitor cocktail, indicating that DOX
internalization was not energy dependent and through diffusion (N = 3, p’s > 0.5). Cell
fluorescence after treatment with the metabolic inhibitor and DOX-DNA-T was
significantly lower than without inhibitor (N = 3, p’s < 0.05). Energy inhibition reduced
MDA-MB-231 fluorescence to 85% of uninhibited fluorescence and MDA-MB-453 to
75%. This indicates that DOX-DNA-T required energy to be internalized. Differences are
not as apparent in confocal images for energy inhibited samples or those treated with
other inhibitors, likely because fewer cells could be analyzed than with flow cytometry.
3.4.1. Clathrin Inhibition. Both MDA-MB-231 and MDA-MB-453 showed
similar trends after incubation with several clathrin-dependent endocytosis inhibitors
(Figure 11). The clathrin inhibitors used interfere with clathrin plasma membrane
distribution and clathrin-coated pits. Sucrose causes clathrin to form microcages, rather
than the normal lattice structures that are required to form endocytic vesicles [35].
Chlorpromazine causes clathrin and the AP-2 protein required for lattice assembly to
relocate from the plasma membrane to internal vesicles [36]. MDC functions by
stabilizing clathrin-coated pits and limits formation of new lattices [37, 38]. Sucrose and
MDC decreased internalization of DOX-DNA-T to a higher degree than Chlorpromazine,
though all showed significant decreases (N = 3, p’s < 0.05). Sucrose decreased
fluorescence to 31 and 35% of the uninhibited fluorescence in MDA-MB-231 and MDAMB-453, respectively. MDC reduced fluorescence to 61% in MDA-MB-231 and 76% in
MDA-MB-453, while Chlorpromazine resulted in decreases to 83% and 76% in the same
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Figure 10. Energy-dependent uptake inhibition of 2 pM of DOX or DOX-DNA-T after
1h. Uninhibited controls after 1h incubation were used to normalize the data set and
inhibited samples were compared to the control using one-tailed t-tests, p’s < 0.05. N = 3.
Scale bar is 50 pm, 40x oil objective.
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Figure 11. Clathrin-dependent uptake inhibition of 2 pM DOX-DNA-T after 1h.
Uninhibited control fluorescence of DOX-DNA-T after 1h incubation was used to
normalize the data set and inhibited samples were compared to the control using one
tailed t-tests, p’s < 0.05. N = 3. Scale bar is 50 pm, 40x oil objective.
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respective cell lines. Sucrose may have decreased fluorescence more than other inhibitors
as it is not as specific [31].
3.4.2. Caveolae Inhibition. Caveolin-dependent endocytosis was inhibited with
filipin and nystatin pre-incubation (Figure 12). Both sequester and deplete cholesterol
from the membrane, which is required for caveolar invagination and lipid-raft-dependent
internalization [31, 39]. Filipin and nystatin significantly inhibited DOX-DNA-T uptake
in both cell lines (N = 3, p’s < 0.05). MDA-MB-231 fluorescence was reduced to 83% of
the control using filipin and to 71% using nystatin. MDA-MB-453 incubation with filipin
reduced cell fluorescence to 63% and nystatin reduced it to 71%.
3.4.3. Macropinocytosis Inhibition. Macropinocytosis inhibitors significantly
reduced the fluorescence of cells (Figure 13). Cyt D alters the polymerization of actin
[40], on which macropinocytosis is dependent [41]. EIPA inhibits Na+/H+ exchange,
insulting in alterations in submembrane pH that affect actin remodeling GTPases [42].
MDA-MB-231 cell fluorescence was reduced to 80% of the control using EIPA and to
73% using Cyt D. With MDA-MB-231, EIPA reduction was significant (N = 3, p < 0.05)
but Cyt D was slightly out of the significance range (N = 3, p = 0.07), likely due to higher
variation. Both inhibitors significantly reduced the fluorescence in MDA-MB-453 cells,
with EIPA decreasing it to 83% and with Cyt D to 73% (N = 3, p’s < 0.05).

4. DISCUSSION

The flexible shape and enhanced tumor retention, along with biocompatibility,
makes DNA origami an interesting drug carrier [20]. Although DNA nanostructures have
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Figure 12. Caveolin-dependent uptake inhibition of 2 pM DOX-DNA-T after 1h.
Uninhibited control fluorescence of DOX-DNA-T after 1h incubation was used to
normalize the data set and inhibited samples were compared to the control using one
tailed t-tests, p’s < 0.05. N = 3. Scale bar is 50 pm, 40x oil objective.
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the potential to overcome resistance and reduce systematic toxicity [13, 14], their exact
cellular uptake mechanism was not well understood. Uptake mechanism and subcellular
localization influence drug delivery efficacy and need to be considered when designing
drug carriers. The stability of DNA nanostructures in physiological environments has
been a concern in vivo due to endogenous nucleases [43]. Despite concerns, DNA
nanostructures maintain their integrity in cell medium for up to 12 hours at the
concentration of FCS tested, enough time for adequate circulation and cellular uptake
[44, 45].
The anticancer efficacy of drug-loaded DNA origami has been shown to be shapedependent in vivo [18]. In our study, the decrease in viability after exposure to DOX and
DOX-DNA-T was significant and differed between time-points and concentrations. DOX
alone was more toxic overall. DOX-DNA-T seemed to have a delayed toxicity in the cell
lines, based on both viability and apoptosis analyses. This may have been due to the
origami slowly releasing the DOX. Since DNA nanostructures sequester loaded
anthracyclines and have a delayed killing effect, systemic exposure and off-targeting can
be reduced as the origami have time to passively accumulate in tumors. Interestingly,
DOX-DNA-T seemed to modulate the differences in DOX toxicity between the two cell
lines, with both cell lines having a very similar decrease in viability. Extending the time
points analyzed would likely reveal higher efficiency in DOX-DNA-T killing as cell
death seemed delayed. There was a sharp decrease in viability at higher concentrations of
DOX-DNA-T after 48 hours and this trend is likely to continue. Zeng et al. were able to
show similar killing efficiencies in MDA-MB-231 cells between DOX and several DOXloaded DNA origami shapes after 96 hours [15].
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Induction of apoptosis at most concentrations and time points was consistent with
the decreases observed in viability. DOX-DNA-T treatment resulted in less apoptosis
based on flow cytometry and microscopy analysis. However, at higher concentrations and
longer times, where DOX and DOX-DNA-T viability reduction was similar, the two
treatments did not result in similar amounts of apoptosis. This indicates that DOX-DNAT may be killing cells by a different mechanism, or that cells exposed to DOX-DNA-T
apoptosis faster at these concentrations and were dead before the analysis occurred,
resulting in lower total apoptosis recorded. It is also possible that DOX-DNA-T induced
more necrosis rather than just apoptosis. Cultures had more debris after treatment with
DOX-DNA-T compared to DOX alone. When cells undergo necrosis, they rapidly lose
membrane integrity and cellular contents are released into the surroundings [46], which
may be the cause of the debris and potential faster cell death observed. However, further
experimentation is required to differentiate between death mechanisms.
Although DNA-T sequesters DOX initially, the drug slowly dissociates from the
complexes. Zeng et al. showed that there was not a significant difference in DOX release
from origami between 6.6 and 7.4 pH [15]. DOX release was around twice as high at 4.5
pH, the pH of lysosomes. The differences in drug release at different pH likely play a role
in drug dynamics within cells, especially if the carrier interacts with lysosomes.
However, the differences observed in toxicity were likely not due to differences in media
pH, as all cell culture media pH was close to neutral, even after 48 hours of cell growth.
As DOX is a small molecule, it was expected that the drug would not be localized
in certain areas within cells, but diffuse evenly throughout the cytoplasm. Dispersed
DOX would also have a higher chance to attack the nucleus than if it were trapped in
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specific areas of the cells, which would explain the higher killing. After 1-hour
incubation DOX appeared to be diffused throughout the cells. However, it was found that
free DOX localized into lysosomes after 24 and 48 hours. Along with time-dependent
localization, DOX localization appeared to be concentration dependent. DOX was more
evenly distributed in the cells at the 10 pM concentration used for apoptosis analysis
compared to the 2 pM used for subcellular localization. Cells may be able to pack DOX
into lysosomes to sequester the drug, if the concentration is low enough or the exposure
time is shorter. This mechanism seems likely, as DOX enters into cells by diffusion and
would not be localized within the lysosomes after endocytosis and endosome evolution
into lysosomes. DOX being diffused in cells after 1 hour and appearing to become
localized into the lysosomes overtime supports this. This is also in agreement with
previous work which has shown DOX can be trapped inside synthetic liposomes that
have a low internal pH (4.6) compared to the environment (7.5) [47]. It has been
speculated that DOX may become trapped inside membranes with low internal pH due to
DOX protonation and gaining charge [47]. Gaining charge would prevent DOX from
diffusing, as charged molecules are unable to pass through lipid membranes [48].
Without a sequestering mechanism, DOX would likely just diffuse out of the
lysosomes if pushed inside. MDA-MB-453 cells had noticeably smaller lysosomes, and
were also more susceptible to DOX at concentrations in the middle of the tested range. At
high concentrations or long periods of exposure, it may be the case that cells do not have
sufficient lysosomal capacity or free lysosomal protons to sequester DOX. MDA-MB453 cells may reach their sequestering limit before MDA-MB-231 and thus die at lower
concentrations of the drug. It is unknown what the threshold concentration of DOX might
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be for this mechanism in live cellular systems. A previous study has shown nuclear
localization after 72 hours using the same concentration of DOX (2 pM) [15]. It is
possible more DOX was able to enter cells after 72-hour incubation and avoided being
sequestered. However, epifluorescent imaging or fixing cells may have produced
artifacts, resulting in the appearance of nuclear localization. Epifluorescence
microscopes capture light from the entire cell, so fluorescence inside the cytoplasm above
the nucleus can appear as nuclear localization. Fixation can also result in artificial entry
of compounds into cells [49]. Confocal microscopy utilizes lasers to take images of
singular planes within cells, allowing clearer images to be captured.
The localization of DOX was altered by loading it into DNA-T. DOX-DNA-T
was expected to be localized within cell lysosomes, the opposite of the expected outcome
for DOX alone. However, relatively few lysosomes showed localization with DOXDNA-T compared to DOX alone. DOX-DNA-T was instead more evenly spread
throughout the cells at both time points and concentrations imaged. This may have been
due to the higher concentration of internalized DOX facilitated by DNA-T. As
endosomes evolve into lysosomes, they fuse with vesicles from the Golgi apparatus and
become acidified [50]. During acidification and when lysosomes maintain their low pH
by pumping in protons, if acidification is prevented by molecules acting as “proton
sponges,” lysosomes will keep transporting protons into themselves [51]. However, the
lysosome will also begin to transport chloride ions inside in order to maintain their
charge, which will cause water to influx to the higher concentration, leading to lysosomal
swelling and bursting due to osmotic pressure [51]. High concentrations of DOX or DNA
origami may act as proton sponges, as DOX becomes protonated inside lysosomes and
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DNA has a negatively charged backbone. It is likely that DOX-DNA-T is originally
localized in endosomes after endocytosis. DOX and DOX-DNA-T may be released from
the endosomes due to bursting. Bursting lysosomes release toxic substances and may
attribute to the sharp decline in cell health when treated with DOX-DNA-T, as lysosomal
swelling and lysis is associated with increased cytotoxicity [51, 52]. This might explain
why MDA-MB-453 seemed to have lower lysosomal localization of DOX-DNA-T, if
they have smaller lysosomal capacity and their lysosomes with internalized DOX-DNA-T
lyse quickly. This process may result in higher cellular DNA damage and cause the cells
to die faster or necrose, preventing the total apoptotic population from being detected.
Generally, necrosis is less desirable in vivo than apoptosis because of the release of
inflammatory substances and wastes from unorganized cell death [46]. Nonetheless,
DNA-T allows DOX to avoid sequestering by lysosomes initially. After 48 hours, DOXDNA-T lysosomal localization appeared to increase in the cells but this fluorescence may
have been DOX dissociated from the DNA-T.
Localization and apoptosis imaging studies revealed higher fluorescence of
internalized DOX when loaded into DNA-T. Uptake of DOX and DOX-DNA-T was
analyzed at 2 pM to reveal the differences between internalization quantity and route.
Although the viability of the two cell lines differed after 24- and 48-hour DOX exposure,
their DOX internalization appeared to be reaching a threshold. This may have been due to
DOX diffusion eliminating the concentration gradient between the internal and external
environment of the cells, allowing only so much DOX to be internalized. Binding of
DOX to internal cell structures or entrapment in lysosomes would decrease the
concentration of free DOX inside cells and reestablish a small concentration gradient
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overtime, leading to the slight upward trend observed over long exposure periods [29].
While uptake between 0 and 4 hours was similar between the free and carried drug,
DOX-DNA-T showed higher uptake at 24 and 48 hours, indicating DNA-T facilitated
drug entry. Since internalized DOX was already bound in DNA-T, this may have also
encouraged DOX diffusion from external DNA-T that released DOX into the culture
media. Enhanced accumulation may aid in killing cancers that have developed resistance
to the drug as exposure time and dose is increased [14]. MDA-MB-453 showed lower
uptake of DOX-DNA-T after 24 and 48 hours compared to MDA-MB-231, even though
their viability was similar after DOX-DNA-T exposure. This may have been due to
MDA-MB-453 having a lower ability to localize DOX-DNA-T in lysosomes or other
factors such as differences in metabolic function between the cell lines, different uptake
mechanisms being damaged after longer exposure to DOX, or different methods of DOXDNA-T expulsion.
DOX internalization by diffusion was confirmed as fluorescence was not
significantly different from metabolic-inhibited internalization. Cells treated with
metabolic inhibitors actually showed slightly higher DOX uptake on average. This is
consistent with a proposed mechanism which states that DOX enters by diffusion and is
actively pumped out of cells [28, 30]. Energy-dependent pumps would not function in the
presence of metabolic inhibitors and cause DOX concentration to be increased inside
cells.
DOX-DNA-T internalization appeared to be by a different mechanism than free
DOX. Inhibition of all pathways studied resulted in decreased fluorescence of
internalized DOX when it was carried by DNA-T. Unlike free DOX, incubation with
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metabolic inhibitors reduced internalized DOX-DNA-T significantly, indicating a
dependence on energy. The highest decrease in fluorescence was observed using clathrin
and caveolin/lipid-raft inhibitors, indicating that DOX-DNA-T uptake is reliant on
various endocytosis mechanisms. Negatively charged DNA nanostructures likely interact
with positively charged membrane molecules on the cell surface and induce endocytosis.
It must also be considered that many pharmacological inhibitors effect multiple pathways
[31]. For instance, MDC interacts with transglutaminases, which are important for actin
assembly [31, 37]. Sucrose is not very specific and can block the formation of membrane
invaginations not coated with clathrin [31]. EIPA may alter endocytosis involving
clathrin and it has been suggested that Cyt D may block most forms of endocytosis [31,
53]. Thus, using complementary inhibitors provides strong support for the use of various
specific pathways. To confirm that DNA origami does not prefer specific pathways,
siRNA inhibition of essential proteins utilized in each pathway would be necessary. It is
also a possibility that DNA-T could be labeled separately from DOX to further analyze
the uptake, but sources have indicated that conjugated dyes may become dissociated from
DNA after internalization [54]. Uptake inhibition of DOX-DNA-T may not have been as
efficient as possible due to DOX being released from DNA origami in solution and
entering cells by diffusion.
Along with siRNA testing, further studies with various nanostructure shapes and
sizes will enable us to identify if DNA origami is preferentially taken up by a pathway
dependent on specific proteins and the optimal geometry to achieve the highest transport
efficiency and cellular uptake. It would be most ideal to deploy a quantitative structure
activity relationship (QSAR) analysis to test different shapes and sizes of DNA origami
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for finding a relationship between structure and function. The most effective
nanostructure derived from such an analysis can be used in a targeted delivery system.
One such target could be the urokinase-type plasminogen activator receptor (uPAR),
which is upregulated in some TNBCs [55]. The TNBC cell lines MDA-MB-231 (high
uPAR expression) and MDA-MB-453 (low uPAR) were tested to further this goal in
future studies. The functionalization capacity of DNA origami holds many potentials.
However, despite the unknowns that still need to be elucidated, DNA origami research
may lag due to concerns about its stability.

5. CONCLUSIONS

DNA-T is able to facilitate DOX internalization by an energy-dependent
endocytosis mechanism. The carrier is able to circumvent differences in DOX toxicity
between cell lines and DOX sequestering in lysosomes. The toxicity of DOX was delayed
when loaded into DNA-T, likely due to slow release from the nanostructures. The
mechanism of cell death may differ when using DNA-T as a carrier for DOX. The higher
concentration of DOX internalized with DNA-T indicates therapeutic concentrations can
be lowered with similar effects, as long as exposure time is sufficient.
Cancer is a devastating disease and many chemotherapies leave patients
debilitated, especially in cases like TNBC where harsh treatment is the only option. Drug
delivery to tumor sites can decrease the harm chemotherapies inflict on healthy tissue and
decrease overall patient morbidity. More treatment options give patients and doctors
alternatives which may be better suited to individual care. The mechanism of DNA
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nanostructure uptake is now better understood, allowing these factors to be considered
when delivering drugs and developing DNA origami as a drug carrier system.
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2. CONCLUSIONS

DNA is a highly therapeutic molecule, with the potential to alter cell protein
expression and carry drugs into cells. A large number of DNA delivery tools have been
explored and it is apparent that delivery technologies will continue to develop in order to
improve overall patient outcome. DNA nanostructures are a promising delivery method
due to programmability and modification. They facilitate drug delivery into cells, showed
a delayed toxicity that allows cells to uptake ample amounts of the complex, and require
energy to be internalized most efficiently. Loading DOX into DNA origami can reduce
systemic exposure by sequestering the drug. Facilitation of DOX entry using DNA
origami may allow therapeutic doses to be lowered with adequate exposure time.
However, the optimal size and shape of origami has yet to be determined. Further studies
need to be conducted in order to discover the optimal geometry for drug delivery and to
increase origami stability for use in vivo. Full understanding of the uptake mechanism
will allow better design of DNA origami as a drug carrier system.
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APPENDIX

PAPER II SUPPLEMENTARY FIGURES

Supplementary Figure 1. 24h DOX localization in MDA-MB-231. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 2. 24h DOX localization in MDA-MB-453. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 3. 24h DOX-DNA-T localization in MDA-MB-231. Blue is
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale
bar is 10 pm.
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Supplementary Figure 4. 24h DOX-DNA-T localization in MDA-MB-453. Blue is
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale
bar is 10 pm.
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Supplementary Figure 5. 48h DOX localization in MDA-MB-231. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 6. 48h DOX localization in MDA-MB-453. Blue is Hoechst, green
is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50 pm in images of
field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale bar is 10 pm.
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Supplementary Figure 7. 48h DOX-DNA-T localization in MDA-MB-231. Blue is
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale
bar is 10 pm.
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Supplementary Figure 8. 48h DOX-DNA-T localization in MDA-MB-453. Blue is
Hoechst, green is DOX, and red is (A) LysoTracker or (B) MitoTracker. Scale bar is 50
pm in images of field. XY, YZ, and XZ images are the area in the yellow box, 5x, Scale
bar is 10 pm.
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